Pancreatic neoplasm
MONDO:0021040A benign or malignant neoplasm involving the pancreas.
Also known as: neoplasm of pancreas, neoplasm of the pancreas, pancreas neoplasm, pancreas neoplasm (disease), pancreas tumor, pancreas tumour, pancreatic neoplasm, pancreatic tumor
2904 clinical trials for this condition and its sub-types, 926 tagged with Pancreatic neoplasm itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Pancreatic neoplasm
-
Malignant pancreatic neoplasm 899 trials · 1,444 incl. sub-types
4 sub-types
- Malignant exocrine pancreas neoplasm 4 trials · 1,053 incl. sub-types Sub-types →
- Pancreatic endocrine carcinoma 12 trials Sub-types →
- Pancreas lymphoma 0 trials Sub-types →
- Pancreas sarcoma 0 trials
-
Pancreatic exocrine neoplasm 1 trial · 1,068 incl. sub-types
5 sub-types
- Malignant exocrine pancreas neoplasm 4 trials · 1,053 incl. sub-types Sub-types →
- Cystic tumor of the pancreas 17 trials · 24 incl. sub-types Sub-types →
- Pancreatic cystadenoma 1 trial · 7 incl. sub-types Sub-types →
- Pancreatic serous cystic neoplasm 1 trial Sub-types →
- Benign neoplasm of exocrine pancreas 0 trials
-
Pancreatic neuroendocrine neoplasm 9 trials · 85 incl. sub-types
2 sub-types
- Pancreatic neuroendocrine tumor 60 trials · 77 incl. sub-types Sub-types →
- Pancreatic endocrine carcinoma 12 trials Sub-types →
-
Benign neoplasm of pancreas 7 trials
2 sub-types
- Benign neoplasm of exocrine pancreas 0 trials
- Pancreatic lipomatosis duodenal stenosis 0 trials
-
Adenoma of pancreas 1 trial
-
GCGR-related hyperglucagonemia 0 trials
Most studied deeper sub-types
Showing the 400 most recently updated of 457 trials in this tab.
-
Can a cancer vaccine train the body to fight advanced tumors?
Cure CompletedThis phase 1 trial is testing an experimental therapeutic cancer vaccine called AST-021p in people with advanced solid tumors that no longer respond to standard treatments. The goal is to see if the vaccine is safe and can trigger an immune response against the cancer. Participan…
Phase 1 • Sponsor: Aston Sci. Inc. • Aim: Cure
Last updated Jul 24, 2026 00:00 UTC
-
Custom-Made cancer vaccine tested in 25 patients
Vaccine CompletedThis study tested whether a personalized vaccine could be safely made and given to 25 adults with advanced cancers that cannot be cured. The vaccine was custom-made for each person. The main goal was to check for side effects and see if the approach is feasible.
Phase 1 • Sponsor: Aaron Miller • Aim: Vaccine
Last updated Jun 27, 2026 12:00 UTC
-
Targeted pill shows promise for rare genetic tumor types
Disease control CompletedThis phase 2 study tested the drug erdafitinib in 316 adults and children with advanced solid tumors that have specific FGFR gene mutations or fusions. The main goal was to see if the drug could shrink tumors. Participants took erdafitinib tablets daily. The study is now complete…
Phase 2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Experimental drug TdCyd aims to reactivate Tumor-Fighting genes in advanced cancer
Disease control CompletedThis early-phase trial tested a new drug called TdCyd in 27 adults with advanced solid tumors that had stopped responding to standard treatments. The drug is designed to turn back on genes that may slow tumor growth. The main goal was to find a safe dose and check for side effect…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New drug combo aims to boost cancer treatment
Disease control CompletedThis early-phase trial tested whether adding nilotinib (a pill) to paclitaxel (a chemotherapy) is safe and tolerable for people with advanced solid tumors that no longer respond to standard treatments. The study included 47 adults and children aged 12 and older. Researchers aimed…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New cocktail of three drugs tested for tough bladder cancers
Disease control CompletedThis early-phase trial tested a combination of two chemotherapy drugs (gemcitabine and carboplatin) plus lenalidomide, a drug that blocks blood vessel growth in tumors, in 18 adults with advanced solid tumors, especially urothelial (bladder) cancer. The main goal was to find the …
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New drug combo takes on tough cancers in early trial
Disease control CompletedThis early-phase trial tested a new drug called vilastobart, alone or with another drug (atezolizumab), in 125 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. Researchers also looke…
Phase 1/2 • Sponsor: Xilio Development, Inc. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New hope for pancreatic cancer? early trial combines novel drug with chemo and immunotherapy
Disease control CompletedThis early-phase study tests a new drug called AB680, combined with immunotherapy (zimberelimab) and two chemotherapy drugs (nab-paclitaxel and gemcitabine), in people with advanced pancreatic cancer that has spread. The main goals are to check safety and find the right dose. Abo…
Phase 1 • Sponsor: Arcus Biosciences, Inc. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Can cutting arginine from the diet starve solid tumors?
Disease control CompletedThis phase 1 trial is testing whether a diet that severely limits arginine—an amino acid some tumors depend on—is safe and might help control solid tumors. About 25 adults with solid tumors will follow a specially designed low-arginine liquid diet for two 3-week cycles while cont…
Phase 1 • Sponsor: West China Hospital • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New drug SG1827 enters first human tests for Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tests a new drug, SG1827, in people with advanced solid tumors that have stopped responding to standard treatments or have no standard therapy available. The main goals are to check the drug's safety, find the best dose, and get a first look at whether it c…
Phase 1 • Sponsor: Hangzhou Sumgen Biotech Co., Ltd. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Electric field therapy combined with chemo shows promise for tough pancreatic cancer
Disease control CompletedThis pilot study tested a wearable device that delivers low-intensity electric fields (TTFields) together with immunotherapy (atezolizumab) and two chemotherapy drugs (gemcitabine and nab-paclitaxel) in 84 people with metastatic pancreatic cancer who had not received prior treatm…
Phase 2 • Sponsor: NovoCure Ltd. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can a triple therapy shrink pancreatic tumors enough for complete surgery?
Disease control CompletedThis phase II trial tests whether giving chemotherapy and proton beam radiation before surgery can help people with borderline-resectable pancreatic cancer. The goal is to shrink the tumor enough so that surgeons can remove it completely, with no cancer cells left at the edges. P…
Phase 2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New radiation approach targets tough pancreatic tumors
Disease control CompletedThis study tests whether giving higher doses of radiation, guided by MRI, can help people with pancreatic cancer that cannot be removed by surgery. Participants must have already had several months of chemotherapy without the cancer spreading. The goal is to see if this approach …
Phase 2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Herbal hope: new combo therapy targets advanced pancreatic cancer
Disease control CompletedThis study tested whether adding a Chinese herbal formula (QingyiHuaji) to standard chemotherapy helps people with stage IV pancreatic cancer live longer. About 305 adults with advanced pancreatic cancer were randomly assigned to receive either the herbal formula plus chemo or a …
Phase 3 • Sponsor: Fudan University • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a Two-Drug combo tame Hard-to-Treat pancreatic cancer?
Disease control CompletedThis phase II trial tests whether combining niraparib and dostarlimab can control metastatic pancreatic cancer in people who carry BRCA1/2 or PALB2 gene mutations. Niraparib blocks enzymes that cancer cells need to grow, while dostarlimab helps the immune system attack the tumor.…
Phase 2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Fiber fuel: could a High-Fiber diet boost cancer treatment?
Disease control CompletedThis study looks at whether eating a high-fiber diet (over 21 grams per day) can change gut bacteria and improve the immune system's ability to fight solid tumors like colorectal cancer. About 25 adults with solid tumors will follow this diet to see if it is safe and helps with t…
Phase 1 • Sponsor: West China Hospital • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can one extra stitch in pancreatic surgery get patients eating again sooner?
Disease control CompletedThis trial tests whether adding a Braun anastomosis, an extra connection between two parts of the small intestine, during standard pancreatic surgery helps prevent delayed gastric emptying. Delayed gastric emptying is a common complication where the stomach is slow to empty food,…
Sponsor: Radboud University Medical Center • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New cocktail aims to outsmart pancreatic cancer
Disease control CompletedThis early-phase trial tests a combination of two immunotherapy drugs (nivolumab and ipilimumab), a vaccine targeting TGFβ-15, and targeted radiation for pancreatic cancer that has not responded to standard treatments. The goal is to see if this mix can safely boost the immune sy…
Phase 1 • Sponsor: Inna Chen, MD • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can a new antibody help the immune system fight Hard-to-Treat tumors?
Disease control CompletedThis trial tests an experimental drug called SNS-101, which targets a protein called VISTA that may help tumors evade the immune system. Researchers give SNS-101 alone or with another immunotherapy, cemiplimab, to adults with advanced solid tumors that have not responded to stand…
Phase 1/2 • Sponsor: Sensei Biotherapeutics, Inc. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New combo therapy shows promise for tough pancreatic cancers
Disease control CompletedThis study tested two different treatment plans for people with a specific type of pancreatic cancer that is on the edge of being removable by surgery. 130 patients received either chemotherapy alone or chemotherapy plus radiation before surgery. The goal was to see which approac…
Phase 2 • Sponsor: Institut de Cancérologie de Lorraine • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Drug combo shows promise in Hard-to-Treat cancers
Disease control CompletedThis phase 1 trial tested the combination of dasatinib (a pill) and bevacizumab (an infusion) in 50 adults with advanced solid tumors that no longer respond to standard treatments. The goal was to find the safest dose and see how well the two drugs work together to slow cancer gr…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can an experimental drug shrink advanced solid tumors?
Disease control CompletedThis phase 1 trial tests an experimental drug called MRG003 in people with advanced solid tumors, including colorectal cancer, head and neck squamous cell carcinoma, and nasopharyngeal carcinoma. The study aims to find a safe dose and to see whether the drug can shrink tumors. Pa…
Phase 1 • Sponsor: Lepu Biopharma Co., Ltd. • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New pill aims to keep chemo on track for GI cancer patients
Disease control CompletedThis study tests whether avatrombopag, a pill that boosts platelet production, can help people with gastrointestinal cancer who develop low platelets from chemotherapy. About 60 participants will receive either avatrombopag or a placebo. The goal is to see if the drug can raise p…
Phase 2 • Sponsor: Hanny Al-Samkari, MD • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat cancers
Disease control CompletedThis early-phase study tests an experimental drug called MK-6837, given alone or with another drug (pembrolizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug sh…
Phase 1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New drug combo shows promise in halting advanced cancers
Disease control CompletedThis early-phase trial tested a combination of two drugs, vandetanib and everolimus, in 151 people with advanced or metastatic cancer that had stopped responding to standard treatments. The goal was to find the safest dose and see if the combination could slow or stop cancer grow…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Can a new chemo combo outsmart small cell lung cancer?
Disease control CompletedThis trial is testing whether a new form of chemotherapy called PLX038 can be safely combined with the PARP inhibitor rucaparib to shrink tumors in people with small cell lung cancer, small cell cancer outside the lungs, or other solid tumors. The study has two parts: first, find…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Can a new drug formulation shrink Hard-to-Treat neuroendocrine tumors?
Disease control CompletedThis phase 2 trial is testing an investigational drug called nab-sirolimus in people with advanced neuroendocrine tumors (NETs) of the gastrointestinal tract, lung, or pancreas. Participants must have had up to two prior lines of therapy (excluding somatostatin analogs) and must …
Phase 2 • Sponsor: Aadi Bioscience, Inc. • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New 3-Week radiation combo could tame pancreatic cancer
Disease control CompletedThis study tests a 3-week course of radiation (using photons or protons) combined with chemotherapy for people with pancreatic cancer that hasn't spread. The goal is to see if this shorter treatment is safe and effective, either before surgery or as the main therapy. Researchers …
Sponsor: Mayo Clinic • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New drug candidate CBX-12 tested in patients with Hard-to-Treat cancers
Disease control CompletedThis study tested an experimental drug called CBX-12 in 69 adults with advanced solid tumors (like ovarian, lung, breast, or colon cancer) that had stopped responding to standard therapies. The main goals were to check the drug's safety, find the best dose, and see if it could sh…
Phase 1/2 • Sponsor: Cybrexa Therapeutics • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
New oral drug targets Cancer's growth engine in advanced tumours
Disease control CompletedThis trial investigates an experimental oral drug, LY3143921 hydrate, which blocks a protein called Cdc7 that cancer cells need to divide. It is being tested in adults with advanced solid tumours, including colorectal, ovarian, lung, and pancreatic cancers, that have not responde…
Phase 1 • Sponsor: Cancer Research UK • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
Can a new drug combo shrink Hard-to-Treat tumors?
Disease control CompletedThis trial is testing whether an experimental drug called JS015, when combined with standard chemotherapy or immunotherapy, is safe and effective for people with advanced solid tumors that have not responded to prior treatment. The study includes patients with certain cancers lik…
Phase 1/2 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Experimental COM902 drug shows promise in early cancer trial
Disease control CompletedThis early-phase study tested an experimental drug called COM902, alone or with other drugs, in 94 people with advanced cancers like ovarian, lung, and colon cancer. The main goal was to check safety and find the right dose. Researchers also looked for early signs that the drug m…
Phase 1 • Sponsor: Compugen Ltd • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a black seed extract boost immunotherapy against a rare cancer?
Disease control CompletedThis pilot trial is testing whether adding NP-101, a compound from black seed oil, to two immunotherapy drugs (nivolumab and ipilimumab) can help control advanced or metastatic extra-pulmonary neuroendocrine carcinoma (EP-NECA) that has progressed after initial treatment. About 1…
Phase 1 • Sponsor: Amr Mohamed MD • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a modified herpes virus turn the tide against advanced cancer?
Disease control CompletedThis early-stage trial is testing an investigational therapy called OH2, a modified herpes simplex virus designed to infect and destroy cancer cells while also stimulating the immune system. The study will evaluate OH2 alone or in combination with the immunotherapy drug pembroliz…
Phase 1/2 • Sponsor: Binhui Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a new drug tame advanced solid tumors?
Disease control CompletedThis early-stage trial is testing an experimental drug called AEB1102 in people with advanced solid tumors that have not responded to standard treatments or for which no standard treatment exists. The main goal is to find the highest dose that is safe and to understand the drug's…
Phase 1 • Sponsor: Immedica Pharma AB • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can an old malaria drug boost Radiation's power against pancreatic cancer?
Disease control CompletedThis phase 2 trial is testing whether adding hydroxychloroquine to standard radiation and chemotherapy before surgery can better control pancreatic cancer. About 50 people with resectable pancreatic cancer will receive either proton or photon radiation along with capecitabine and…
Phase 2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New pill targets tough cancers in early human trial
Disease control CompletedThis early-phase trial is testing an oral drug called ATRN-119 in 132 people with advanced solid tumors that have specific DNA repair mutations. The main goals are to check safety, how the drug moves through the body, and whether it can shrink tumors. Participants must be able to…
Phase 1/2 • Sponsor: Aprea Therapeutics • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Can a targeted antibody give pancreatic cancer chemo a boost?
Disease control CompletedThis trial is testing whether adding an experimental antibody called XB2001 to a standard chemotherapy regimen can help people with advanced pancreatic cancer. The study has two parts: first, it finds the safest dose of XB2001, then it compares the antibody plus chemo against a p…
Phase 1/2 • Sponsor: XBiotech, Inc. • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New drug SKB410 enters human testing for Hard-to-Treat cancers
Disease control CompletedThis early-stage study tests a new drug called SKB410 in about 54 adults with advanced solid tumors who have no standard treatment options left. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants receive multiple doses…
Phase 1 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Can an RNAi drug shrink Hard-to-Treat tumors?
Disease control CompletedThis phase 1 trial is testing an experimental drug called STP707 in people with advanced or metastatic solid tumors that have not responded to standard treatments. The study aims to find a safe dose and see whether the drug can slow or shrink tumors. Participants receive STP707 b…
Phase 1 • Sponsor: Sirnaomics • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Radioactive drug shows promise against advanced cancers
Disease control CompletedThis study tested a new radioactive drug, 177Lu-NeoB, in 35 adults with advanced solid tumors that have a specific marker (GRPR). The goal was to check safety, find the best dose, and see if it shrinks tumors. It is an early-stage trial, so it focuses on safety and dosing, not a …
Phase 1/2 • Sponsor: Advanced Accelerator Applications • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Custom-Made cancer vaccine shows promise in early trial
Disease control CompletedThis completed phase I/IIb trial tested a personalized vaccine made from each patient's unique tumor mutations. Eight adults with advanced solid tumors or high recurrence risk received the vaccine alongside an immune booster and later checkpoint inhibitors. The goal was to see if…
Phase 1/2 • Sponsor: Seqker Biosciences, Inc. • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Can High-Dose vitamin c boost Chemo's punch against pancreatic cancer?
Disease control CompletedThis trial is testing whether adding high-dose vitamin C (ascorbic acid) to a standard three-drug chemotherapy cocktail can safely and effectively control metastatic pancreatic cancer in people who have not yet received any treatment. The study enrolls adults with stage IV pancre…
Phase 1/2 • Sponsor: HonorHealth Research Institute • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Can High-Dose vitamin c boost chemo against pancreatic cancer?
Disease control CompletedThis phase II trial tests whether adding high-dose vitamin C (ascorbate) to standard chemotherapy (gemcitabine and nab-paclitaxel) can help people with metastatic pancreatic cancer live longer. About 40 participants are randomly assigned to receive either standard chemo alone or …
Phase 2 • Sponsor: University of Iowa • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Can a cancer pill keep working outside the lab? a Real-World test begins
Disease control CompletedThis study monitors the safety and effectiveness of the drug olaparib (Lynparza) in people with ovarian, breast, prostate, or pancreatic cancer who are prescribed it as part of routine care in South Korea. Researchers will track side effects and how long the cancer stays under co…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Can a new infusion drug tame advanced solid tumors?
Disease control CompletedThis early-phase trial is testing an experimental drug called SM3321 in people with advanced solid tumors that have stopped responding to standard treatments. The main goal is to see if the drug is safe and tolerable, and to find the best dose. Participants receive SM3321 as a we…
Phase 1 • Sponsor: Beijing StarMab Biomed Technology Ltd • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Four-Drug cocktail aims to shrink pancreatic tumors before surgery
Disease control CompletedThis phase II trial tests whether a combination of four chemotherapy drugs—paclitaxel protein bound, gemcitabine, cisplatin, and hydroxychloroquine—given before surgery can improve outcomes for people with pancreatic cancer that has not spread. The study focuses on patients whose…
Phase 2 • Sponsor: HonorHealth Research Institute • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Experimental drug JS015 takes first steps against advanced solid tumors
Disease control CompletedThis early-stage trial tests an experimental drug called JS015 in people with advanced solid tumors who have run out of standard treatment options. The main goal is to check the drug's safety, find the best dose, and see how the body processes it. Up to 12 participants will recei…
Phase 1 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Could a radiofrequency knife beat the stapler for safer pancreas surgery?
Disease control CompletedThis trial tests whether using a radiofrequency device to cut the pancreas during distal pancreatectomy reduces the chance of a pancreatic fistula (a leak of digestive fluids) compared to the standard stapler method. About 112 adults having this surgery for benign or malignant tu…
Sponsor: Patricia Sanchez Velazquez • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Experimental drug SHR-7367 takes first step against advanced cancers
Disease control CompletedThis early-stage trial tests an experimental drug called SHR-7367 in people with advanced solid tumors that have spread or cannot be removed by surgery. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. About 22 participants will …
Phase 1 • Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Could conscious sedation replace general anesthesia for gallbladder drainage?
Disease control CompletedThis study tests whether endoscopic ultrasound-guided gallbladder drainage can be safely performed using conscious sedation given by the endoscopist, instead of deep sedation or general anesthesia. The trial enrolls elderly, high-risk patients with acute cholecystitis who are not…
Sponsor: Azienda Unita Sanitaria Locale di Piacenza • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Experimental pill takes on advanced cancers alongside immunotherapy
Disease control CompletedThis early-phase trial tests an experimental oral drug, MK-6598, both by itself and in combination with the immunotherapy pembrolizumab (Keytruda) in adults with advanced or metastatic solid tumors. The main goals are to check safety, find the right dose, and see early signs of t…
Phase 1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New antibody drug takes on Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested a new drug called CHS-388 in 145 people with advanced solid tumors (kidney, liver, or lung cancer) that had stopped responding to standard treatments. CHS-388 is an antibody that blocks a protein called IL-27, which may help the immune system fight c…
Phase 1 • Sponsor: Coherus Oncology, Inc. • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Pancreatic cancer showdown: surgery first or chemo first?
Disease control CompletedThis completed study looked at whether giving chemotherapy before surgery (neoadjuvant chemo) helps people with resectable pancreatic cancer live longer compared to having surgery right away. Thirty patients took part. The main goal was to see which approach leads to better overa…
Sponsor: Minia University • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New drug PEP-010 shows promise in early cancer trial
Disease control CompletedThis early-phase trial tests a new drug called PEP-010 in people with advanced solid tumors that have spread. The study checks if PEP-010 is safe alone or with chemotherapy (paclitaxel or gemcitabine). About 57 adults with metastatic pancreatic, ovarian, or other solid cancers wi…
Early phase 1 • Sponsor: Institut Curie • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New drug combo takes on advanced cancers in first human trial
Disease control CompletedThis early-phase study tests an experimental drug called ANV600, given alone or with the immunotherapy Keytruda, in 240 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and see if the drug can shrink tumors. Beca…
Phase 1/2 • Sponsor: Anaveon AG • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat cancers
Disease control CompletedThis trial investigates a type of immunotherapy called CAR-T cells that are designed to recognize and attack cancer cells carrying a protein called CEA. The study includes adults with advanced gastric, colon, rectal, esophageal, or pancreatic cancer who have not responded to at l…
Phase 1/2 • Sponsor: Chongqing Precision Biotech Co., Ltd • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New drug combo aims to shrink pancreatic tumors before surgery
Disease control CompletedThis study tests whether adding the drug surufatinib to standard chemotherapy can help shrink pancreatic tumors enough to allow successful surgery. It involves 29 adults with locally advanced or borderline resectable pancreatic cancer. The main goal is to see how many tumors can …
Phase 2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New combo attack on tough pancreatic cancer shows promise in early trial
Disease control CompletedThis study tests a treatment plan for people with advanced pancreatic cancer that has spread to a major artery. Participants receive chemotherapy and radiation before surgery, then more chemo after. The goal is to see if this approach is safe and helps patients live longer. The t…
Phase 1/2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Smart sugar sensors may improve recovery from complex pancreatic surgery
Disease control CompletedThis study tests whether using a real-time continuous glucose monitor (RT-CGM) during pancreaticoduodenectomy (a complex surgery) helps keep patients' blood sugar in a safe range and improves recovery. About 246 adults scheduled for this surgery will be randomly assigned to stand…
Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Cord blood cells engineered to fight stomach and pancreatic cancers
Disease control CompletedThis early-phase study tested a new treatment using immune cells from cord blood, modified to target a protein called Claudin18.2 found on some cancer cells. Ten adults with advanced stomach or pancreatic cancer who had no other options received these cells to find the safest dos…
Phase 1 • Sponsor: Zhejiang Provincial People's Hospital • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Lab-Made immune protein takes on advanced cancers in first human test
Disease control CompletedThis study tests a new drug called pegilodecakin, a lab-made version of a natural immune protein (interleukin-10), in people with advanced solid tumors such as melanoma, lung, breast, prostate, ovarian, kidney, colorectal, and pancreatic cancers. The drug is given as a daily shot…
Phase 1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat cancers
Disease control CompletedThis early-stage trial tests a new type of cell therapy called CEA-targeted CAR-T for people with advanced colorectal, esophageal, stomach, or pancreatic cancers that have stopped responding to standard treatments. The therapy involves taking a patient's own immune cells, enginee…
Phase 1 • Sponsor: Chongqing Precision Biotech Co., Ltd • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Hand exercises may shield nerves from chemo side effects
Disease control CompletedThis study tests whether a special hand therapy program can prevent chemotherapy-induced nerve damage in the hands of people with pancreatic cancer. Participants are randomly assigned to either the hand therapy or traditional occupational therapy. The goal is to see if the hand t…
Sponsor: HonorHealth Research Institute • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New pill takes on tough cancers: first human trial begins
Disease control CompletedThis early-phase study tests a new oral drug called TT125-802 in 50 adults with advanced solid tumors (like lung cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. It is a fi…
Phase 1 • Sponsor: TOLREMO therapeutics AG • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Two-Drug combo aims to stall rare gut tumors
Disease control CompletedThis trial tests whether combining two drugs—RAD001 (everolimus) and octreotide depot—can slow tumor growth in people with advanced low-grade neuroendocrine cancer (carcinoid or islet cell tumors) that has spread or cannot be removed surgically. Participants take RAD001 daily by …
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Could a common blood pressure pill boost radiation against tough pancreatic tumors?
Disease control CompletedThis early-phase study tests whether adding losartan (a blood pressure medicine) to a shorter, higher-dose radiation treatment can help people with pancreatic cancer that is hard to remove surgically. The main goal is to check for side effects and find the safest dose. About 22 a…
Phase 1 • Sponsor: University of Utah • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Experimental drug hopes to boost chemo against tough pancreatic cancer
Disease control CompletedThis trial investigates whether adding antroquinonol (Hocena) to standard chemotherapy (nab-paclitaxel and gemcitabine) can safely treat people with metastatic pancreatic cancer that has not yet been treated. The study has two phases: first, finding the best dose, and second, che…
Phase 1/2 • Sponsor: Golden Biotechnology Corporation • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Experimental cell therapy takes aim at Hard-to-Treat cancers
Disease control CompletedThis early-stage trial tests an experimental cell therapy called IBR854 in people with advanced solid tumors that cannot be surgically removed or have spread. The main goals are to check the treatment's safety and find the right dose. Participants receive the cells by infusion tw…
Phase 1 • Sponsor: Imbioray (Hangzhou) Biomedicine Co., Ltd. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control CompletedThis study tests an experimental drug called XmAb24306, given alone or with another cancer drug (atezolizumab), in people with advanced solid tumors that cannot be cured. The main goal is to check the drug's safety and how the body processes it. About 195 participants will take p…
Phase 1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New pill takes aim at Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tests an experimental tablet called YZJ-5053 in people with advanced solid tumors who have no standard treatment options left. The main goals are to find a safe dose and check for side effects. Researchers will also look at how the drug moves through the bo…
Phase 1 • Sponsor: Shanghai Haiyan Pharmaceutical Technology Co., Ltd. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Promising combo tackles tough cancers in early trial
Disease control CompletedThis early-phase study tested the safety of combining two drugs—pembrolizumab (an immunotherapy) and AMG386 (which targets blood vessel growth)—in 62 people with advanced solid tumors like melanoma, ovarian, renal, or colorectal cancer. The main goals were to find the safest dose…
Phase 1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New drug combo shows promise in early cancer trial
Disease control CompletedThis early-stage trial tested a new drug called BGB-15025, alone or with another drug (tislelizumab), in 157 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the best dose. The study is now complete, …
Phase 1 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New cancer drug combo tested in early human trial
Disease control CompletedThis early-phase trial tested an experimental drug called IOS-1002, given alone or with the immunotherapy pembrolizumab, in 47 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. Research…
Phase 1 • Sponsor: ImmunOs Therapeutics AG • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New drug duo shows promise for Hard-to-Treat cancers
Disease control CompletedThis phase 2 study tested a combination of two drugs—olaparib and pembrolizumab—in 333 adults with advanced solid tumors that have specific DNA repair problems (HRR mutations or HRD). The goal was to see if the combo could shrink tumors or slow their growth. Participants had alre…
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug IBI129 tested in humans for first time against Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested an experimental drug called IBI129 in 36 adults with advanced solid tumors that could not be removed by surgery or had spread. The main goals were to find a safe dose and check for side effects. Researchers also looked for any signs that the drug mig…
Phase 1/2 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New cancer drug CFI-402257 enters first human trial
Disease control CompletedThis Phase 1 trial tested an investigational oral drug called CFI-402257 in 52 people with advanced solid tumors, including breast cancer, that had stopped responding to standard treatments. The main goal was to find a safe dose and check how the drug moves through the body. It w…
Phase 1 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Robot or scalpel? european trial tests less invasive pancreatic cancer surgery
Disease control CompletedThis trial compares two types of surgery for pancreatic cancer in the body or tail of the pancreas: minimally invasive (laparoscopic or robot-assisted) versus traditional open surgery. The goal is to see if the less invasive approach can remove the tumor just as completely. Adult…
Sponsor: University Hospital, Montpellier • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New immunotherapy cocktail aims to simplify cancer treatment
Disease control CompletedThis study tested a fixed-dose combination of two immunotherapy drugs, tiragolumab and atezolizumab, given together as a single infusion every three weeks. The trial enrolled 64 people with advanced solid tumors that express a protein called PD-L1. The main goal was to check the …
Phase 2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo takes on advanced cancers in early trial
Disease control CompletedThis early-phase trial tested an experimental drug called KVA12123, given alone or with the immunotherapy Keytruda, in 40 adults with advanced solid tumors (like lung, breast, or colon cancer) that had stopped responding to standard treatments. The main goals were to check safety…
Phase 1/2 • Sponsor: Kineta Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Promising cocktail may shrink pancreatic tumors before surgery
Disease control CompletedThis Phase II trial tested a combination of chemotherapy drugs (FOLFIRINOX) plus the blood pressure drug losartan, followed by proton radiation, in 50 people with locally advanced pancreatic cancer. The goal was to see if this approach could shrink tumors enough to allow complete…
Phase 2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo shows promise in early cancer trial
Disease control CompletedThis early-phase trial tested a new drug called RO7496353 combined with an immunotherapy (atezolizumab) and sometimes chemotherapy in 102 people with advanced lung, stomach, or pancreatic cancer. The main goal was to check safety and side effects. Researchers also looked at how t…
Phase 1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Immune cells armed with antibody take on pancreatic cancer
Disease control CompletedThis trial tested a new treatment called EGFR BATs for people with advanced pancreatic cancer. The treatment uses a patient's own immune cells, armed with a special antibody, to target cancer cells. The study included 22 participants who had already received chemotherapy. The goa…
Phase 1/2 • Sponsor: University of Virginia • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug shows promise in helping immune system fight advanced cancers
Disease control CompletedThis study tested a drug called PF-06801591 in 155 people with advanced solid tumors or non-small-cell lung cancer. The drug works by blocking a protein that stops the immune system from attacking cancer cells. The goal was to check safety, how the drug moves through the body, an…
Phase 1/2 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Radiation and immunotherapy combo shows promise in small cancer study
Disease control CompletedThis pilot study tested whether combining high-dose radiation therapy with the immunotherapy drug pembrolizumab (Keytruda) could boost the immune system's ability to fight advanced solid tumors. Twenty-one patients with various advanced cancers received the combination either at …
Phase 1 • Sponsor: James Larner, MD • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug duo shows promise for tough cancers
Disease control CompletedThis study tested two experimental drugs (AK104 and AK117) together, sometimes with chemotherapy, in 128 people with advanced solid tumors. The goal was to see if the combination is safe and can shrink tumors. It focused on patients with stomach, esophageal, or other advanced can…
Phase 1/2 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New immunotherapy combo takes on tough pancreatic cancer
Disease control CompletedThis phase 2 trial tested whether adding an immunotherapy drug called botensilimab to standard chemotherapy could help people with metastatic pancreatic cancer who had already progressed on a common chemo regimen (FOLFIRINOX). The study enrolled 81 participants and compared the c…
Phase 2 • Sponsor: Agenus Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New pill shows promise in shrinking Hard-to-Treat breast tumors
Disease control CompletedThis study tested a new oral drug called BGB-43395 in 33 Chinese patients with advanced or metastatic HR+/HER2- breast cancer and other solid tumors. The drug blocks a protein (CDK4) that helps cancer cells grow. The goal was to find a safe dose and see if it can shrink tumors wh…
Phase 1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Experimental vaccine targets Hard-to-Treat cancers in first human test
Disease control CompletedThis early-phase trial tested a new type of vaccine made from a patient's own immune cells (dendritic cells) that are engineered to target a protein called WT1 found in many cancers. Ten people with advanced esophageal, pancreatic, ovarian, or liver cancer received six vaccines o…
Phase 1/2 • Sponsor: University Hospital, Antwerp • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control CompletedThis early-phase study tested a new drug called BGB-C354, alone or with an immunotherapy (tislelizumab), in 63 people with advanced solid tumors that had not responded to standard treatments. The main goals were to check safety and find the right dose. Researchers also looked for…
Phase 1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New shot form of cancer drug tested in 142 patients
Disease control CompletedThis study tested a new under-the-skin shot version of the cancer drug pembrolizumab (Keytruda) in 142 people with advanced solid tumors. The goal was to see how well the body absorbs the drug compared to the standard IV infusion. Researchers also checked for side effects and how…
Phase 1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New drug XTX202 tested in patients with advanced cancers
Disease control CompletedThis study tested a new drug called XTX202 in 95 people with advanced solid tumors that had not responded to standard treatments. The goal was to check safety, find the right dose, and see if the drug could shrink tumors. The trial is now complete.
Phase 1/2 • Sponsor: Xilio Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New drug cocktail shows promise against tough pancreatic cancer
Disease control CompletedThis completed phase 1/2 trial tested an experimental drug called Y101D combined with standard chemotherapy (gemcitabine and nab-paclitaxel) as a first treatment for 71 people with advanced pancreatic cancer. The goal was to find a safe dose and see if the combo helps shrink tumo…
Phase 1/2 • Sponsor: Wuhan YZY Biopharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New drug cocktail aims to tackle childhood cancers that Won't quit
Disease control CompletedThis early-phase study tested a combination of two drugs, cabozantinib and 13-cis-retinoic acid, in 15 children whose solid tumors had come back or were not responding to standard treatments. The main goal was to find the safest dose and understand side effects. The study did not…
Phase 1 • Sponsor: Peter Zage • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug combo tested for tough cancers
Disease control CompletedThis early-stage trial tested a new drug called AZD6244 combined with standard chemotherapies in 140 people with advanced solid tumors (breast, colon, lung, melanoma, kidney). The main goal was to see if the combination is safe and tolerable, and to find the best dose. Researcher…
Phase 1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Experimental combo targets Hard-to-Treat GI cancers
Disease control CompletedThis early-phase trial tested two drugs together—pembrolizumab (Keytruda) and XL888—in 47 people with advanced gastrointestinal cancers like colorectal and pancreatic cancer that had spread or could not be removed. The main goal was to find the safest dose and check for side effe…
Phase 1 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New hope for tough pancreatic cancer? drug combo trial shows promise
Disease control CompletedThis study tested a new drug called NIS793 added to standard chemotherapy for people with metastatic pancreatic cancer that has spread. The goal was to see if the combination could help patients live longer by reducing scar tissue in the tumor. About 511 adults with this advanced…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New drug combo shows promise in early pancreatic cancer trial
Disease control CompletedThis early-phase trial tested whether adding a new drug called NP137 to standard chemotherapy (mFOLFIRINOX) is safe and could help shrink tumors in people with locally advanced pancreatic cancer that cannot be removed by surgery. 43 participants received the combination. The main…
Phase 1 • Sponsor: University Hospital, Grenoble • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Could a simple anesthesia change boost pancreatic cancer survival?
Disease control CompletedThis study looked at whether using epidural anesthesia (a numbing shot in the back) during pancreatic cancer surgery helps people live longer and stay cancer-free longer. About 540 adults having surgery for pancreatic cancer took part. The goal was to see if this type of pain con…
Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Less surgery may be enough for rare pancreatic tumor, study suggests
Disease control CompletedThis study looked at 708 patients with a rare, low-grade pancreatic tumor called solid pseudopapillary neoplasm. Researchers compared a less invasive surgery that saves healthy pancreas tissue to a more extensive surgery that removes more of the organ. They also examined whether …
Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New cocktail of four chemo drugs shows promise for tough pancreatic cancer
Disease control CompletedThis phase 2 trial tested a combination of four chemotherapy drugs—irinotecan liposome, oxaliplatin, 5-fluorouracil, and levoleucovorin—in 41 Japanese adults with metastatic pancreatic cancer who had not received prior treatment. The goal was to see how well the drugs shrank tumo…
Phase 2 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New drug duo aims to tackle Hard-to-Treat cancers
Disease control CompletedThis study tested a new drug called TJ004309, either alone or combined with another drug called Toripalimab, in 225 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to find the safest dose and see early signs of effectiveness. The…
Phase 1/2 • Sponsor: TJ Biopharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New hope for pancreatic cancer? drug combo trial shows promise
Disease control CompletedThis study tested whether adding two experimental drugs (TTX-030 and budigalimab) to standard chemotherapy could help people with metastatic pancreatic cancer live longer without their disease getting worse. 194 adults who had not yet received treatment for their advanced cancer …
Phase 2 • Sponsor: Trishula Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug cocktail aims to fight advanced cancers
Disease control CompletedThis early-phase study tested a daily combination of two oral drugs, axitinib and everolimus, in 19 people with advanced solid tumors, particularly kidney cancer. The main goal was to find the safest dose by monitoring side effects in the first month. Researchers also tracked how…
Phase 1 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control CompletedThis study tested a new oral drug called HMPL-453 tartrate, either alone or combined with chemotherapy or an immunotherapy (toripalimab), in 190 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and see if th…
Phase 1/2 • Sponsor: Hutchison Medipharma Limited • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control CompletedThis early-stage study tested two drugs, cabozantinib and pamiparib, together in 44 people with advanced solid tumors that had stopped responding to standard treatments. The goal was to find the safest dose and understand side effects. The drugs work by blocking certain enzymes t…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug shows promise in early trial for advanced cancers
Disease control CompletedThis early-phase study tested a new drug called CCT3833 in 31 adults with advanced solid tumours, including melanoma. The main goal was to find a safe dose and check for side effects. Researchers measured how the drug moves through the body and looked for the best dose to use in …
Phase 1 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New cancer drug PM14 enters human testing for advanced tumors
Disease control CompletedThis early-phase trial tested a new drug called PM14 in 126 people with advanced solid tumors that had no standard cure. The main goals were to find a safe dose and check for early signs of tumor shrinkage. The drug was given by IV infusion on different schedules. This is a first…
Phase 1 • Sponsor: PharmaMar • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New cocktail of chemo drugs shows promise for tough pancreatic cancer
Disease control CompletedThis study tested a combination of three chemotherapy drugs (paclitaxel protein bound, gemcitabine, and cisplatin) in 34 people with metastatic pancreatic cancer that had not been treated before. If the cancer got worse, a fourth drug (paricalcitol) was added. The goal was to see…
Phase 2 • Sponsor: HonorHealth Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Yeast vaccine shows promise in stopping Cancer's return
Disease control CompletedThis early-stage study tested a custom-made yeast vaccine designed to train the immune system to recognize and attack leftover cancer cells. Five adults with various cancers (like colorectal, breast, or lung) who had completed initial treatment received the vaccine. The goal was …
Phase 1 • Sponsor: NantBioScience, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Experimental cancer drug injected directly into tumors shows early promise
Disease control CompletedThis early-phase trial tested a new drug called KL340399, which is injected directly into tumors to activate the immune system. It involved 6 adults with advanced solid tumors who had no other treatment options. The main goals were to check safety, find the right dose, and see if…
Phase 1 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Experimental cancer drug KL340399 tested in 21 patients
Disease control CompletedThis early-phase trial tested a new drug called KL340399 in 21 adults with advanced solid tumors that had stopped responding to standard treatments. The drug works by activating the STING pathway to help the immune system fight cancer. The main goals were to check safety, find th…
Phase 1 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Custom-Made vaccine targets pancreatic cancer in early human test
Disease control CompletedThis phase 1 trial tested a personalized vaccine made from each patient's unique cancer mutations (neoantigens) combined with an immune booster (poly-ICLC) in 33 people with pancreatic cancer. The vaccine was given after standard chemotherapy, either before or after surgery. The …
Phase 1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New combo shows promise for Hard-to-Treat cancers
Disease control CompletedThis study tested a combination of two drugs, lenvatinib and pembrolizumab, in 611 people with advanced cancers like breast, ovarian, stomach, colorectal, brain, bile duct, or pancreatic cancer that had stopped responding to standard treatments. The goal was to see if the combo c…
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New cancer drug HBM1020 tested in tiny early trial
Disease control CompletedThis early-phase study tested a new drug, HBM1020, in 17 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. The drug was given by IV every three weeks. Because this is a Phase 1 trial, i…
Phase 1 • Sponsor: Harbour BioMed US, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Experimental drug PRL3-ZUMAB shows promise in Hard-to-Treat cancers
Disease control CompletedThis study tested a new drug called PRL3-ZUMAB in 14 people with advanced solid tumors (like stomach or liver cancer) that stopped responding to standard treatments. The drug was given every two weeks to see if it could shrink tumors or stop them from growing. Researchers also lo…
Phase 2 • Sponsor: National Cancer Centre, Singapore • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New ALK inhibitor ensartinib tested in first human trial for lung cancer
Disease control CompletedThis study tested a new oral drug called ensartinib (X-396) for the first time in humans. It involved 131 people with advanced solid tumors, including those with ALK-positive non-small cell lung cancer. The goal was to find the safest dose and see if the drug could shrink tumors.…
Phase 1/2 • Sponsor: Xcovery Holdings, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New drug ProAgio tested in patients with advanced cancers
Disease control CompletedThis early-stage trial tested a new drug, ProAgio, in 46 people with advanced solid tumors, including pancreatic cancer, who had already tried other treatments. The main goal was to find a safe dose and check for side effects. The study did not aim to cure the disease, but to con…
Phase 1 • Sponsor: ProDa BioTech, LLC • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New cocktail of drugs shows promise for tough pancreatic cancer
Disease control CompletedThis study tested a combination of four drugs (tadalafil, pembrolizumab, ipilimumab, and CRS-207) in 17 people with advanced pancreatic cancer that had worsened after at least one round of chemotherapy. The goal was to see if the combination was safe and could shrink tumors. The …
Phase 2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Experimental antibody HH-101 tested in 12 patients with advanced cancers
Disease control CompletedThis early-stage trial tested an experimental drug called HH-101 in 12 people with advanced solid tumors that had not responded to standard treatments. The main goal was to check the drug's safety and find the right dose. Participants received HH-101 as an IV infusion every three…
Phase 1 • Sponsor: Huahui Health • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New drug cocktail shows promise against tough pancreatic cancer
Disease control CompletedThis study tested a combination of four drugs (paclitaxel protein bound, gemcitabine, cisplatin, and paricalcitol) given before surgery to people with pancreatic cancer that could or could not be removed. The goal was to see if the treatment could shrink tumors and improve surgic…
Phase 2 • Sponsor: HonorHealth Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New cancer drug shows promise in early trial for Tough-to-Treat tumors
Disease control CompletedThis study tested a new drug called FF-10502-01 in 106 adults with advanced solid tumors or lymphomas that had stopped responding to standard treatments. The goal was to find the safest dose and see if the drug could shrink tumors or slow disease progression. While not a cure, th…
Phase 1/2 • Sponsor: Fujifilm Pharmaceuticals U.S.A., Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug targets tough childhood cancers with genetic flaws
Disease control CompletedThis phase 2 trial tested the drug samotolisib in 18 children and young adults with advanced solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that had spread, returned, or stopped responding to treatment. Only patients whose tumors had specific mutations in the TSC or…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Triple chemo cocktail shows promise against tough pancreatic cancer
Disease control CompletedThis phase II trial tested a combination of three chemotherapy drugs (nab-paclitaxel, cisplatin, and gemcitabine) in 42 people with metastatic pancreatic cancer that had not been treated before. The main goal was to see how many patients were alive after 12 months. The study also…
Phase 2 • Sponsor: HonorHealth Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New liposomal chemo cocktail takes on pancreatic cancer
Disease control CompletedThis Phase 3 trial tested a new combination of chemotherapy drugs—irinotecan liposome, oxaliplatin, 5-fluorouracil, and leucovorin—against the standard treatment (nab-paclitaxel plus gemcitabine) in 770 people with metastatic pancreatic cancer who had not received prior chemother…
Phase 3 • Sponsor: Ipsen • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
New drug tested for advanced cancers: early results
Disease control CompletedThis early-phase trial tested a new drug called NOV140101 in 32 adults with advanced solid tumors that had spread or could not be removed by surgery. The main goals were to find the safest dose and check for side effects. The study is complete, but it was too small to determine i…
Phase 1 • Sponsor: Idience Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Tailored chemo doses may help seniors fight pancreatic cancer while staying independent
Disease control CompletedThis study tested a chemotherapy cocktail called FOLFIRINOX in 72 patients aged 70 or older with metastatic pancreatic cancer. The doses were adjusted based on each person's genetics to reduce side effects while still fighting the tumor. The goal was to see if this approach could…
Phase 2 • Sponsor: Institut Cancerologie de l'Ouest • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New Double-Action antibody shows promise against Hard-to-Treat cancers
Disease control CompletedThis phase 2 trial tested an experimental drug called HX009 in 20 adults with advanced solid tumors that had stopped responding to standard treatments. HX009 is a bifunctional antibody designed to block two proteins (CD47 and PD-1) that help tumors hide from the immune system. Th…
Phase 2 • Sponsor: Hangzhou Hanx Biopharmaceuticals, Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New drug takes on tough pancreatic cancer
Disease control CompletedThis study tested a new drug called HCW9218 in 21 people with advanced pancreatic cancer that had stopped responding to standard treatments. The drug is designed to boost the immune system and block a protein that helps tumors grow. The main goals were to check safety and find th…
Phase 1/2 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New radiation approach targets inoperable pancreatic tumors
Disease control CompletedThis early-phase trial tested a new type of radiation called carbon ion therapy for people with locally advanced pancreatic cancer that cannot be removed by surgery. Fourteen participants received increasing doses of carbon ion radiation along with chemotherapy. The main goal was…
Phase 1 • Sponsor: Montefiore Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New drug cocktail tried against tough pancreatic cancer
Disease control CompletedThis study tested a combination of two oral drugs, ribociclib and everolimus, in 12 people with metastatic pancreatic cancer that had stopped responding to standard chemotherapy. The goal was to find the right dose and see if it could slow tumor growth. The trial was small and ea…
Phase 1/2 • Sponsor: Georgetown University • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Triple-Drug immunotherapy cocktail shows promise in advanced tumors
Disease control CompletedThis early-phase trial tested whether combining the experimental drug relatlimab with other immunotherapies (nivolumab plus either BMS-986205 or ipilimumab) is safe and can shrink tumors in people with advanced solid cancers. A total of 229 participants with various incurable, ad…
Phase 1/2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Experimental combo targets Hard-to-Treat pancreatic cancer
Disease control CompletedThis early-phase trial tested two drugs—binimetinib and hydroxychloroquine—in 34 people with a specific type of advanced pancreatic cancer (KRAS-mutant) that had spread. The goal was to find the safest dose of hydroxychloroquine when used with binimetinib, and to see if the combi…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New hope for Hard-to-Treat cancers? utidelone trial underway
Disease control CompletedThis phase 2 trial tests the drug utidelone in 126 people with advanced solid tumors (excluding breast, lung, and colorectal cancers) that have not responded to standard treatments. The study aims to see if the drug can shrink tumors and how safe it is. Participants receive utide…
Phase 2 • Sponsor: Beijing Biostar Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New combo tackles tough pancreatic cancer
Disease control CompletedThis study tested an experimental immunotherapy called indoximod added to standard chemotherapy (gemcitabine and nab-paclitaxel) in 157 people with metastatic pancreatic cancer. The goal was to find a safe dose and see if the combination helps people live longer. The trial has co…
Phase 1/2 • Sponsor: NewLink Genetics Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Surgeons test wrapping trick to prevent pancreatic leaks after whipple
Disease control CompletedThis study tested a new way to reconnect the pancreas to the intestine during Whipple surgery for certain cancers. The new method uses a stent and wraps the connection with omentum (fatty tissue) to try to prevent leaks. 48 patients were split into two groups to compare the new t…
Sponsor: Theodor Bilharz Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Diabetes drug plus chemo shows promise in early cancer trial
Disease control CompletedThis early-phase trial tested the safety of combining pioglitazone (a diabetes drug) with carboplatin (a chemotherapy) in 14 people with advanced solid tumors that could not be cured with standard treatments. The goal was to find the best dose and see if the combination is safe. …
Phase 1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New pill plus chemo shows early promise in tough pancreatic cancer
Disease control CompletedThis early-phase trial tested an experimental oral drug called IOA-289 combined with standard chemotherapy (gemcitabine and nab-paclitaxel) in 16 people with metastatic pancreatic cancer. The main goal was to check safety and find the right dose. Researchers also looked at how th…
Phase 1/2 • Sponsor: iOnctura • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Early trial checks safety of experimental cancer drug
Disease control CompletedThis early-phase study tested a new drug called BAT4706 in 28 adults with advanced solid tumors or melanoma who had no other good treatment options. The main goal was to find a safe dose and check for side effects. This was not a cure study; it aimed to gather safety information …
Phase 1 • Sponsor: Bio-Thera Solutions • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Double-Drug attack on tough pancreatic cancer shows promise in small trial
Disease control CompletedThis study tested a combination of two oral chemotherapy drugs, vemurafenib and sorafenib, in 10 people with advanced pancreatic cancer that has a specific genetic change called a KRAS mutation. All participants had already tried at least two standard treatments without success. …
Phase 2 • Sponsor: HonorHealth Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New pill shows promise against advanced cancers in early trial
Disease control CompletedThis study tested a new cancer drug called brigimadlin (BI 907828) in 266 adults with advanced solid tumors that had spread or stopped responding to standard treatments. The goal was to find a safe dose and see if the drug could shrink tumors. Brigimadlin is an MDM2 inhibitor tak…
Phase 1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New artery chemo method may boost survival in hard-to-treat pancreatic cancer
Disease control CompletedThis study looked at 60 people with advanced pancreatic body or tail cancer that couldn't be removed by surgery. It compared a targeted treatment called splenic artery infusion chemotherapy (SAIC), which delivers chemo directly to the tumor's blood supply, with standard chemo giv…
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Generic cancer pill matches Brand-Name drug in study
Disease control CompletedThis study checked if a generic version of the cancer drug trifluridine/tipiracil works the same as the brand-name drug Lonsurf in 76 patients with solid tumors. Participants took the drug under fasting and fed conditions to compare how the body absorbs it. The goal was to show t…
Sponsor: Shandong New Time Pharmaceutical Co., LTD • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New chemo cocktail targets liver tumors in pancreatic cancer
Disease control CompletedThis phase 2 trial tested a combination of chemotherapy drugs given directly into the liver artery for people with pancreatic cancer that had spread only to the liver and stopped responding to standard treatment. The 40 participants received a mix of oxaliplatin, irinotecan lipos…
Phase 2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New drug cocktail targets Hard-to-Treat gut cancers
Disease control CompletedThis study tested a new cancer drug called ERAS-007, given by mouth, together with other targeted therapies in 101 people with advanced colorectal or pancreatic cancers that have certain gene changes. The main goals were to check safety, find the best dose, and see how the drugs …
Phase 1/2 • Sponsor: Erasca, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New drug combo shows promise in Hard-to-Treat cancers
Disease control CompletedThis early-stage study tested a new drug called DF6215, alone or with another drug (pembrolizumab), in 35 adults with advanced solid tumors that could not be removed by surgery or had spread. The main goals were to find the safest dose and check for side effects. The study is com…
Phase 1 • Sponsor: Dragonfly Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New cancer drug ZN-c3 shows early promise in solid tumor trial
Disease control CompletedThis early-phase study tested a new drug called ZN-c3 (Azenosertib) in 274 adults with various solid tumors. The main goals were to find a safe dose and check for side effects. Researchers also looked for signs that the drug could shrink tumors. This is a first step to see if the…
Phase 1 • Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New immunotherapy combo tackles Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested an experimental drug called DF6002, either alone or combined with the approved immunotherapy nivolumab (Opdivo), in 170 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find th…
Phase 1 • Sponsor: Dragonfly Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New drug targets Hard-to-Treat cancers in early trial
Disease control CompletedThis study tested a new drug called DF1001 in 270 adults with advanced solid tumors that have spread or cannot be removed. The drug works by helping the body's immune cells attack cancer cells. The trial first found the safest dose, then tested it alone or with other cancer drugs…
Phase 1/2 • Sponsor: Dragonfly Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Triple threat: new combo aims to stop pancreatic cancer spread
Disease control CompletedThis phase II trial tested a combination of a pancreatic cancer vaccine (GVAX), an immunotherapy drug (pembrolizumab), and focused radiation (SBRT) in 58 patients with locally advanced pancreatic cancer. The goal was to see if this approach could delay the spread of the cancer to…
Phase 2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New cancer drug RS-0139 tested in humans for first time
Disease control CompletedThis early-phase trial tested a new drug called RS-0139 in 16 people with advanced solid tumors that had stopped responding to standard treatments. The drug is designed to target tumors specifically, and the main goals were to find a safe dose and understand how the body processe…
Phase 1 • Sponsor: RS Arastirma Egitim Danismanlik Ilac Sanayi Ticaret A.S. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Triple drug cocktail targets tough pancreatic cancer
Disease control CompletedThis phase 2 study tested a combination of three drugs—gemcitabine, trastuzumab, and erlotinib—as a first treatment for people with metastatic pancreatic cancer that has spread. The goal was to see if the combination could control tumor growth. 63 patients received the drugs intr…
Phase 2 • Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New Two-Drug cocktail shows promise against tough cancers
Disease control CompletedThis study tested a combination of two drugs—NT-I7 (efineptakin alfa) and pembrolizumab (Keytruda)—in 215 people with advanced solid tumors that had stopped responding to treatment. The goal was to check safety, find the right dose, and see if the combo could shrink tumors. The t…
Phase 1/2 • Sponsor: NeoImmuneTech • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Carbon ion beam takes aim at tough pancreatic tumors
Disease control CompletedThis study tested a special type of radiation called carbon ion therapy for people with pancreatic cancer that cannot be removed by surgery. The goal was to see if this treatment works better than standard radiation at controlling the cancer and helping people live longer. Twenty…
Sponsor: University Hospital Heidelberg • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Virus engineered to fight cancer shows promise in early trial
Disease control CompletedThis early-stage trial tested a modified virus called TILT-123 in 32 people with advanced solid tumors that had not responded to standard treatments. The virus is designed to infect and kill cancer cells while releasing immune-boosting proteins. The main goal was to check safety …
Phase 1 • Sponsor: TILT Biotherapeutics Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Double-Dose chemo strategy shows promise against pancreatic cancer
Disease control CompletedThis study tested a combination of chemotherapy drugs given both before and after surgery for people with early-stage pancreatic cancer. The goal was to shrink the tumor before surgery and kill any remaining cancer cells afterward. 46 participants were enrolled to see if this app…
Phase 2 • Sponsor: Yale University • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Experimental combo targets Hard-to-Treat cancers
Disease control CompletedThis early-phase study tested the safety of combining two drugs—AZD1775 (a pill) and durvalumab (an IV infusion)—in 56 adults with advanced solid tumours that had stopped responding to standard treatments. The goal was to find safe doses and watch for side effects. While not a cu…
Phase 1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Epigenetic and immune drugs join forces against tough tumors
Disease control CompletedThis completed Phase 2 trial tested whether combining an immunotherapy drug (durvalumab) with an epigenetic drug (tazemetostat) can control advanced solid tumors like pancreatic, colorectal, and soft-tissue sarcoma. The study enrolled 164 adults and measured how well the combo sh…
Phase 2 • Sponsor: Institut Bergonié • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New drug cocktail shows promise against tough cancers
Disease control CompletedThis study tested a combination of two experimental drugs, AK112 and AK117, with or without chemotherapy, in 154 people with advanced solid tumors. The goal was to see if the combo could shrink tumors and control the disease. The trial has finished, and researchers are now lookin…
Phase 1/2 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New shot aims to stop Chemo's dangerous side effect
Disease control CompletedThis early-stage trial tested a new drug called PN20 in 24 adults with lymphoma or solid tumors who were getting chemotherapy. The goal was to see if a single injection before chemo could safely prevent a drop in platelets, which can cause bleeding. Researchers checked safety and…
Phase 1 • Sponsor: Chongqing Peg-Bio Biopharm Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New targeted pill shows promise for Hard-to-Treat bile duct cancers
Disease control CompletedThis study tested a new oral drug called RLY-4008 in 490 adults with advanced bile duct cancer or other solid tumors that have specific FGFR2 gene changes. The drug is designed to block the FGFR2 protein, which can drive cancer growth. The trial aimed to find the safest dose and …
Phase 1/2 • Sponsor: Elevar Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New combo shows promise in controlling advanced cancers
Disease control CompletedThis study tested an experimental drug (BMS-986253) combined with standard immunotherapy drugs (nivolumab with or without ipilimumab) in 281 people with advanced cancers like melanoma. The main goals were to check safety and see if tumors shrank. This is a disease-control approac…
Phase 1/2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
CRISPR-Engineered immune cells take on stomach and colon cancers
Disease control CompletedThis trial tested a new approach for people with advanced gastrointestinal cancers that had stopped responding to standard treatments. Doctors removed immune cells from patients' tumors, used CRISPR gene editing to disable a gene called CISH, and then infused the modified cells b…
Phase 1/2 • Sponsor: Intima Bioscience, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Cold virus engineered to attack pancreatic cancer shows promise in early trial
Disease control CompletedThis study tested a modified cold virus called LOAd703 in 51 people with pancreatic cancer. The virus is designed to infect and kill cancer cells while also boosting the immune system. It was given alongside standard chemotherapy, and in some cases an immunotherapy drug, to see i…
Phase 1/2 • Sponsor: Lokon Pharma AB • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New study aims to match pancreatic cancer patients with best chemo
Disease control CompletedThis phase 2 trial tested two standard chemotherapy regimens, Folfirinox and Gemcitabine/nab-paclitaxel, in 150 patients with untreated metastatic pancreatic cancer. The goal was to see which works better and to use lab tests to personalize treatment. The study is complete, and r…
Phase 2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New drug cocktail shows promise for Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested a new drug called BGB-10188, alone or combined with other cancer drugs (zanubrutinib for blood cancers, tislelizumab for solid tumors), in 97 patients whose cancers had returned or stopped responding to treatment. The main goals were to find safe dos…
Phase 1/2 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New pill targets brain tumors with IDH mutations
Disease control CompletedThis early-phase study tested an oral drug called AG-881 in 95 adults with advanced solid tumors, including brain tumors (gliomas), that have specific IDH gene mutations. The main goals were to check safety, find the best dose, and see how the drug works in the body. While not a …
Phase 1 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New drug combo tested for tough pancreatic cancer
Disease control CompletedThis early-phase trial tested whether adding the drug anakinra to standard chemotherapy is safe for people with metastatic pancreatic cancer. Thirteen adults with advanced disease received the combination. The main goal was to check for side effects, not to see if it works.
Phase 1 • Sponsor: Baylor Research Institute • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New hope for cancer patients: drug may prevent Chemo-Induced bleeding risk
Disease control CompletedThis study tested a drug called romiplostim in 165 adults with gastrointestinal, pancreatic, or colorectal cancer who were receiving chemotherapy. The goal was to see if romiplostim could prevent low platelet counts (thrombocytopenia) that often force doctors to delay or reduce c…
Phase 3 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New combo therapy aims to tackle tough pancreatic cancer
Disease control CompletedThis completed phase 2 trial tested whether adding an anti-PD-1 immunotherapy drug to standard chemotherapy (modified-FOLFIRINOX) helps patients with locally advanced or borderline resectable pancreatic cancer. The study enrolled 392 participants and compared the combination agai…
Phase 2 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New combo therapy tested for tough pancreatic cancer
Disease control CompletedThis early-stage study tested whether combining a procedure that uses electrical pulses to destroy tumors (IRE) with an immunotherapy drug (pembrolizumab) is safe for people with locally advanced pancreatic cancer that cannot be removed by surgery. Only 2 participants were enroll…
Phase 1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New oral drug combo shows promise in early cancer trial
Disease control CompletedThis early-phase trial tested two experimental drugs, FdCyd and THU, taken by mouth for advanced solid tumors that had not responded to standard treatments. Fifty-nine adults received the drugs in 21-day cycles to see if they were safe and tolerable. The goal was to find a dose f…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Could chemo before surgery boost survival in pancreatic cancer?
Disease control CompletedThis study tested whether giving chemotherapy before surgery (neoadjuvant chemo) helps people with resectable pancreatic cancer live longer. 153 patients were randomly assigned to either standard surgery followed by chemo, or one of two chemo regimens (FOLFOX or FOLFIRINOX) befor…
Phase 2 • Sponsor: University Hospital, Rouen • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New pill targets rare gene in Hard-to-Treat cancers
Disease control CompletedThis study tested a new pill called larotrectinib in 75 adults with advanced cancers that have a specific gene change (NTRK fusion). The main goals were to check the drug's safety, find the best dose, and see how the body processes it. Participants had no other good treatment opt…
Phase 1 • Sponsor: Bayer • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New cancer pill tested in humans for first time
Disease control CompletedThis early-stage trial tested a new oral drug, MSP008-22, in 7 adults with advanced solid tumors (breast, ovarian, prostate, head and neck cancers) that had spread or could not be removed. The main goal was to find a safe dose and check for side effects. This is a first step to s…
Phase 1 • Sponsor: Godavari Biorefineries Limited • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Pancreatic cancer trial combines chemo with immune boosters
Disease control CompletedThis study tested whether adding two immunotherapy drugs (pembrolizumab and defactinib) to standard chemotherapy before and after surgery could help the body fight pancreatic cancer better. It involved 28 people with early-stage, removable pancreatic cancer. The goal was to see i…
Phase 2 • Sponsor: Lei Zheng • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
First human trial of BI 765049 combo aims to fight hard-to-treat cancers
Disease control CompletedThis early-phase study tests two experimental drugs, BI 765049 and ezabenlimab, in adults with advanced solid tumors like colorectal, lung, and pancreatic cancer. The main goal is to find the highest safe dose of BI 765049 alone and in combination with ezabenlimab. Participants r…
Phase 1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New cancer drug shows promise in early trial
Disease control CompletedThis early-phase trial tested a new immunotherapy drug called BI 754091 in 110 people with advanced solid tumours that had spread or could not be removed surgically. The main goals were to find the safest dose and check for side effects. Researchers also looked for early signs th…
Phase 1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New nanoparticle chemo shows promise in early trial for tough cancers
Disease control CompletedThis early-phase trial tested a new drug called SNB-101 in 21 people with advanced solid tumors (like colorectal, breast, and lung cancers) that had stopped responding to standard treatments. SNB-101 is a nanoparticle version of SN-38, the active part of a common chemotherapy dru…
Phase 1 • Sponsor: SN BioScience • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New injection attacks tumors from inside out
Disease control CompletedThis early-stage trial tested an experimental drug called CyPep-1, injected directly into tumors, either alone or with the immunotherapy pembrolizumab. The study involved 60 adults with advanced solid cancers that had stopped responding to standard treatments. The main goals were…
Phase 1/2 • Sponsor: Cytovation AS • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug combo shows promise in controlling Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested an experimental drug called VS-6766, given alone or with everolimus, in 104 adults with advanced solid tumors or multiple myeloma that had stopped responding to standard treatments. The goal was to find a safe, tolerable dosing schedule and measure h…
Phase 1 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New combo therapy shows promise for tough pancreatic cancer
Disease control CompletedThis study tested a combination of two drugs, pembrolizumab (an immunotherapy) and azacitidine (a drug that affects gene activity), in people with advanced pancreatic cancer that had worsened after initial treatment. The goal was to see if this combination could help control the …
Phase 2 • Sponsor: Susan E. Bates • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New combo therapy shows promise for Hard-to-Treat cancers
Disease control CompletedThis study tested a new immunotherapy drug, ezabenlimab, combined with other cancer medicines in 211 adults with advanced solid tumors that had spread. The goal was to see if the tumors shrank or disappeared. Participants received different drug combinations, and doctors monitore…
Phase 2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug combo shows promise in Hard-to-Treat cancers
Disease control CompletedThis study tested two experimental drugs (BI 754111 and BI 754091) that help the immune system attack cancer. It included 172 adults with advanced solid tumors, including non-small cell lung cancer that had returned after prior treatment. The first part found the safest dose, and…
Phase 1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 08:15 UTC
-
Vitamin d and malaria drug join forces against pancreatic cancer
Disease control CompletedThis phase II trial tested whether adding paricalcitol (a vitamin D drug) and hydroxychloroquine (an autophagy inhibitor) to standard chemotherapy could help shrink tumors in 10 people with advanced or metastatic pancreatic cancer. The goal was to see if the combination improved …
Phase 2 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Experimental CAR-T therapy targets Hard-to-Treat solid tumors
Disease control CompletedThis pilot study tested a new type of immune cell therapy called anti-ALPP CAR-T cells in 5 patients with advanced solid tumors that have a specific marker (ALPP). The goal was to see if the treatment is safe and can shrink tumors. Patients first received chemotherapy to prepare …
Phase 1/2 • Sponsor: Xinqiao Hospital of Chongqing • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Robotic vs open: which whipple surgery is safer for pancreatic cancer?
Disease control CompletedThis study compared miniinvasive (robotic or laparoscopic) Whipple surgery to the traditional open approach in 320 patients with pancreatic, bile duct, or ampulla of Vater cancers. The goal was to see which method leads to fewer complications like pancreatic leaks, bleeding, or i…
Sponsor: State Budget Public Health Institution Scientific Research Institute - Ochapovsky Regional Clinical Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New Immune-Targeting drug tested for stubborn cancers
Disease control CompletedThis early-phase trial tested a new drug called CUE-102 in 42 adults with certain advanced cancers (colorectal, gastric, pancreatic, or ovarian) that had returned or spread despite prior treatments. The drug is designed to help the immune system attack cancer cells that carry a s…
Phase 1 • Sponsor: Cue Biopharma • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Experimental immune therapy takes aim at Hard-to-Treat cancers
Disease control CompletedThis early-phase study tested a new type of immunotherapy called ALPP CAR-T cells in 5 adults with advanced solid tumors that had not responded to standard treatments. The therapy involves genetically modifying a patient's own immune cells to recognize and attack cancer cells tha…
Phase 1/2 • Sponsor: Xinqiao Hospital of Chongqing • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Experimental combo targets Hard-to-Treat cancers
Disease control CompletedThis early-phase study tested an experimental drug called BMS-986288, both by itself and combined with the immunotherapy nivolumab (Opdivo), in 219 people with advanced solid tumors that had worsened after standard treatments. The main goal was to check safety and tolerability, a…
Phase 1/2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Electric field device shows promise in tough pancreatic cancer trial
Disease control CompletedThis phase 3 trial tested a wearable device called Tumor Treating Fields (TTFields) combined with standard chemotherapy for people with locally advanced pancreatic cancer that cannot be removed by surgery. The device sends low-intensity electric fields to the tumor area to disrup…
Phase 3 • Sponsor: NovoCure Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Chemo-Immuno cocktail shows promise in early cancer trial
Disease control CompletedThis early-phase trial tested whether adding two chemotherapy drugs (6-mercaptopurine and 6-thioguanine) to an immunotherapy drug (Atezolizumab) could help treat advanced solid tumors that have stopped responding to standard treatments. The study enrolled 18 adults with metastati…
Phase 1/2 • Sponsor: Kristoffer Rohrberg • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New safety data on LYNPARZA for pancreatic cancer patients with BRCA mutation
Disease control CompletedThis study looked at the safety of LYNPARZA (olaparib) when used as a maintenance treatment after platinum-based chemotherapy in 130 patients with BRCA-mutated pancreatic cancer that could not be surgically removed. Researchers tracked side effects like bone marrow problems, lung…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New combo may extend life in tough pancreatic cancer
Disease control CompletedThis study looked at 211 people with advanced pancreatic cancer whose first treatment (FOLFIRINOX) stopped working or caused too many side effects. Researchers compared a two-drug combination (gemcitabine and paclitaxel) against gemcitabine alone to see if the combo helped people…
Phase 3 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New drug shows promise for Hard-to-Treat cancers with p53 gene
Disease control CompletedThis study tested a new drug called ALRN-6924 in 142 people with advanced solid tumors or lymphomas that have a normal p53 gene. The goal was to see if the drug is safe and can shrink tumors. Participants had cancers that did not respond to standard treatments or had no standard …
Phase 1/2 • Sponsor: Aileron Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New drug JAB-8263 tested in patients with advanced cancers
Disease control CompletedThis early-phase study tested a new drug called JAB-8263 in 41 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find a safe dose and check for side effects. The study is now complete.
Phase 1 • Sponsor: Jacobio Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New cancer drug MRX-2843 enters first human trial
Disease control CompletedThis early-stage trial tested a new drug called MRX-2843 in 42 adults with advanced solid tumors that had spread or come back after other treatments. The main goal was to check safety and find the right dose. Researchers monitored side effects and how the drug moved through the b…
Phase 1 • Sponsor: Meryx, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Experimental antibody combo tackles Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested an experimental drug called ADG116, which helps the immune system attack cancer cells. The study included 72 adults with advanced solid tumors that had stopped responding to standard treatments. Some participants received ADG116 alone, while others g…
Phase 1 • Sponsor: Adagene Inc • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New immune booster FL115 tested in patients with advanced cancers
Disease control CompletedThis early-phase trial tested a new drug called FL115 in 18 adults with advanced solid tumors that had stopped responding to standard treatments. FL115 is designed to strengthen the body's immune cells to fight cancer. The main goal was to check safety and find the right dose, wh…
Phase 1 • Sponsor: Suzhou Forlong Biotechnology Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control CompletedThis early-phase study tested a combination of two experimental drugs (BGB-283 and PD-0325901) in 91 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and see if the drugs could shrink tumors. The trial is no…
Phase 1 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New drug RC88 shows promise in early trial for hard-to-treat cancers
Disease control CompletedThis study tested an experimental drug called RC88 in 198 people with advanced solid tumors that had stopped responding to standard treatments. The goal was to find a safe dose and see if the drug could shrink tumors or slow their growth. The study was completed and looked at sid…
Phase 1/2 • Sponsor: RemeGen Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New drug IBI334 tested on 28 patients with advanced cancer
Disease control CompletedThis study tested a new drug called IBI334 in 28 people with advanced solid tumors that could not be removed by surgery or had spread. The main goals were to check the drug's safety and see if it helps control the cancer. The study is now complete.
Phase 1/2 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New drug ZGGS15 tested in patients with advanced cancers
Disease control CompletedThis early-stage trial tested a new biologic drug called ZGGS15 in 22 adults with advanced solid tumors who had no standard treatment options left. The main goals were to check safety, find the right dose, and look for early signs that the drug might control tumor growth. Partici…
Phase 1 • Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New antibody combo shows promise in early cancer trial
Disease control CompletedThis early-phase study tested an experimental drug called JAB-BX102, alone or with the immunotherapy pembrolizumab, in 21 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose, while also …
Phase 1/2 • Sponsor: Jacobio Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New drug shows promise in early trial for advanced cancers
Disease control CompletedThis early-phase study tested a new drug called BAT8006 in 216 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the best dose for future studies. This is not a cure, but a step toward better control…
Phase 1 • Sponsor: Bio-Thera Solutions • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New pill shows promise in early trial for tough cancers
Disease control CompletedThis early-phase study tested an experimental oral drug called Q702 in 51 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find a safe dose and check for side effects, while also looking at whether the drug could shrink …
Phase 1 • Sponsor: Qurient Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Heat and immune boost: new combo tackles Hard-to-Treat cancers
Disease control CompletedThis trial tested a two-step treatment for people with advanced solid tumors that no longer respond to standard therapies. First, a laser heats and destroys part of the tumor. Then, a drug called IP-001 is injected directly into the treated area to help the immune system recogniz…
Phase 1/2 • Sponsor: Swiss Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New chemo cocktail shows promise against tough pancreatic cancer
Disease control CompletedThis phase II trial tested two chemotherapy combinations as first-line treatment for people with advanced or metastatic pancreatic cancer. One group received a newer regimen called SLOG, while the other got a standard combo called mFOLFIRINOX. The study aimed to see which worked …
Phase 2 • Sponsor: National Health Research Institutes, Taiwan • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New pill JAB-3312 tested in patients with advanced cancers
Disease control CompletedThis early-stage trial tested an oral drug called JAB-3312 in 40 adults with advanced solid tumors (like lung, colon, or breast cancer) that had stopped responding to standard treatments. The main goals were to find a safe dose and check for side effects. Researchers also looked …
Phase 1 • Sponsor: Jacobio Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New cancer drug shows promise in early trial
Disease control CompletedThis phase 1 study tested an experimental drug called LY3039478 in 247 people with advanced or metastatic cancer, including lymphoma. The main goal was to find a safe dose and see how the drug affects the body. Researchers also looked for signs that the drug might shrink tumors.
Phase 1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New drug NB003 tested in 258 patients with advanced cancers
Disease control CompletedThis early-phase trial tested a new drug called NB003 in 258 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check the drug's safety, find the right dose, and see if it could shrink tumors. The study is now complete, an…
Phase 1 • Sponsor: Ningbo Newbay Technology Development Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New drug RC88 shows promise for advanced cancers in early trial
Disease control CompletedThis study tested an injectable drug called RC88 in 41 people with advanced solid tumours who had no other good treatment options. The main goal was to check the drug's safety and find the right dose. The study is now complete, and results will help guide future research.
Phase 1/2 • Sponsor: RemeGen Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New drug cocktail shows promise for tough pancreatic cancer
Disease control CompletedThis phase 2 trial tested a new drug called onvansertib combined with standard chemotherapy for people with metastatic pancreatic cancer that had already been treated once. The study enrolled 41 adults and measured how many patients' tumors shrank. The goal is to find a better se…
Phase 2 • Sponsor: Cardiff Oncology • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Robot surgeons take on pancreatic cancer in major trial
Disease control CompletedThis study compared robotic-assisted pancreatic surgery to the standard open approach for people with pancreatic and related tumors. Researchers wanted to see if robotic surgery could help patients recover faster after the operation. A total of 268 patients took part across multi…
Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New pill shows promise for Hard-to-Treat cancers
Disease control CompletedThis early-phase study tested a new daily pill, ASC61, in 18 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to check the drug's safety and how the body processes it. Researchers looked for side effects and measured tumor respons…
Phase 1 • Sponsor: Ascletis Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New drug combo tested for advanced cancers in asian patients
Disease control CompletedThis early-phase trial tested an experimental drug called ezabenlimab, alone or combined with another drug (BI 754111), in 146 Asian patients with advanced solid tumors. The main goals were to check safety, find the right dose, and see if the combination shrinks tumors in cancers…
Early phase 1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New drug E7090 tested in patients with advanced solid tumors
Disease control CompletedThis early-phase study tested an experimental drug called E7090 in 40 adults with advanced solid tumors that had not responded to standard treatments. The goal was to find the safest dose and check for early signs of effectiveness, especially in patients whose tumors have certain…
Phase 1 • Sponsor: Eisai Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New cancer drug ABBV-155 enters first human tests
Disease control CompletedThis early-phase study tested a new drug called ABBV-155, given alone or with standard chemotherapy (paclitaxel or docetaxel), in 168 adults with advanced solid tumors that had come back or stopped responding to treatment. The main goal was to find a safe dose and check for early…
Phase 1 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Smarter radiation aims to outsmart pancreatic cancer
Disease control CompletedThis phase 2 trial tested whether a new way of targeting radiation (based on where the cancer usually comes back) works better than the standard method for locally advanced pancreatic cancer. 96 patients received either the new or standard radiation. The study looked at how long …
Sponsor: Changhai Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New antibody drug tested in patients with Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested a new drug called BAT6026 in 30 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety and find the best dose. Researchers also looked at how the drug moves through the body …
Phase 1 • Sponsor: Bio-Thera Solutions • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New cancer drug shows promise in early safety trial
Disease control CompletedThis early-stage study tested a new drug called BAT1308 in 59 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find a safe dose and check for side effects. Researchers also looked at how the drug moves through the body. Th…
Phase 1 • Sponsor: Bio-Thera Solutions • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New immunotherapy cocktail shows promise for Hard-to-Treat cancers
Disease control CompletedThis early-stage study tested a fixed-dose combination of two immunotherapy drugs (relatlimab and nivolumab) in 24 Chinese patients with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, how the drugs move through the b…
Phase 1/2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New drug duo shows early promise against advanced cancers
Disease control CompletedThis early-phase study tested a combination of two experimental drugs (AK127 and AK104) in 67 people with advanced or metastatic solid tumours that had stopped responding to standard treatments. The main goals were to check safety and find the right dose, while also looking for s…
Early phase 1 • Sponsor: Akesobio Australia Pty Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Gene-Edited immune cells take on Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested a new treatment called CTX131 for adults with advanced solid tumors that have not responded to standard therapies. The treatment uses donor immune cells that are gene-edited to target a protein called CD70 found on cancer cells. The study enrolled 19…
Phase 1/2 • Sponsor: CRISPR Therapeutics AG • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Radiation plus two immunotherapy drugs shows promise in advanced cancers
Disease control CompletedThis early-phase trial tested a new way to treat advanced cancers that have spread. It combined a special type of radiation with two immunotherapy drugs (MEDI4736 and tremelimumab) to see if the combination is safe and tolerable. The study included 53 adults with advanced melanom…
Phase 1 • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New cancer drug GEN1056 tested in first human trial
Disease control CompletedThis early-stage trial tested a new drug, GEN1056, in 26 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety and find the best dose. Researchers also looked for signs that the drug might shrink tumors.
Phase 1 • Sponsor: Genmab • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Experimental vaccine trains immune system to fight multiple cancers
Disease control CompletedThis study tested a cancer vaccine called ETBX-011 in 43 people with advanced colorectal, lung, breast, or prostate cancers that produce a protein called CEA. The vaccine uses a modified virus to teach the immune system to attack cancer cells making CEA. The main goals were to ch…
Phase 1/2 • Sponsor: NantCell, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Vitamin d derivative tested as chemo booster for pancreatic cancer
Disease control CompletedThis small pilot study tested whether adding a vitamin D-like drug called paricalcitol to standard chemotherapy could help people with advanced pancreatic cancer that had stopped responding. 27 patients received chemotherapy first, then paricalcitol was added if their disease sta…
Phase 2 • Sponsor: Barts & The London NHS Trust • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New hope for pancreatic cancer? immunotherapy cocktails tested in major trial
Disease control CompletedThis study tested several immunotherapy-based drug combinations in 341 people with metastatic pancreatic cancer. Participants were split into two groups: those who had not yet received treatment and those who had already tried one type of chemotherapy. The goal was to see if thes…
Phase 1/2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New cancer drug BR101 enters first human tests
Disease control CompletedThis early-phase trial tested a new drug called BR101 in 15 people with advanced solid tumors that had not responded to standard treatments. The main goals were to check the drug's safety, find the right dose, and see if it shows any signs of shrinking tumors. Participants receiv…
Phase 1 • Sponsor: BioRay Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New combo tackles tough pancreatic cancer
Disease control CompletedThis phase 2 trial tested two drugs, cabozantinib and pembrolizumab, in 21 people with metastatic pancreatic cancer that had worsened after standard treatment. The goal was to see if the combination could slow cancer growth. The study is complete, and results may help guide futur…
Phase 2 • Sponsor: Joseph Kim • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New immunotherapy combo shows promise for advanced cancers
Disease control CompletedThis study tested an experimental drug called BMS-986249, either alone or combined with the immunotherapy nivolumab (Opdivo), in 356 people with advanced solid tumors. The main goals were to check safety and find the right dose. Researchers also looked at whether the tumors shran…
Phase 1/2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New triple therapy shows promise for resistant cancers
Disease control CompletedThis early-phase trial tested a combination of three drugs—afuresertib, sintilimab, and chemotherapy—in 22 adults with solid tumors (including lung, cervical, and stomach cancers) that had stopped responding to prior immunotherapy. The goal was to find a safe dose and see if the …
Phase 1/2 • Sponsor: Laekna Limited • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New drug combo shows promise in early cancer trial
Disease control CompletedThis early-phase trial tested a new immunotherapy drug called BDB001, alone or combined with atezolizumab (Tecentriq), in 40 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the best dose, and see if t…
Phase 1 • Sponsor: Eikon Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New drug combo shows promise in early cancer trial
Disease control CompletedThis early-phase trial tested a new immunotherapy drug called BDB001, both alone and combined with pembrolizumab, in 87 adults with advanced solid tumors that had progressed after standard treatments. The main goals were to check safety and find the best dose. The study is comple…
Phase 1 • Sponsor: Eikon Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Early trial of BDB018 combo for tough cancers wraps up with just one patient
Disease control CompletedThis early-phase study tested a new immunotherapy drug called BDB018, given alone or with pembrolizumab, in people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. Only one person took part, …
Phase 1 • Sponsor: Eikon Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New combo targets DNA repair to fight pancreatic cancer
Disease control CompletedThis study tested a new combination of drugs (ABT-888 plus chemotherapy) in 64 people with pancreatic cancer that had spread. The goal was to see if adding ABT-888, which blocks cancer cells from fixing DNA damage, could make chemotherapy work better and shrink tumors. The study …
Phase 1/2 • Sponsor: Georgetown University • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New drug combo shows promise in early cancer trial
Disease control CompletedThis early-phase study tested a new drug called boserolimab (MK-5890), either alone or combined with the immunotherapy pembrolizumab (KEYTRUDA), in 182 adults with advanced solid tumors, including lung and breast cancers. The main goals were to check safety and how the drug moves…
Phase 1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New drug aims to boost immune system against tough cancers
Disease control CompletedThis early-phase trial tested a new drug called HCW9218 in 18 people with advanced solid tumors that had not responded to at least two prior treatments. The drug is designed to both activate immune cells and block signals that help tumors grow. The main goal was to find a safe do…
Phase 1 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Cancer drug tazemetostat gets Long-Term safety check in rollover trial
Disease control CompletedThis study offers continued access to tazemetostat for 58 people with various cancers who already benefited from the drug in earlier trials. The main goal is to monitor long-term safety and side effects. Participants must have shown clinical benefit from tazemetostat before joini…
Phase 1/2 • Sponsor: Epizyme, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New radiation approach aims to tame tough pancreatic tumors
Disease control CompletedThis pilot study tested a highly targeted form of radiation called stereotactic body radiation therapy (SBRT) in 36 patients with pancreatic cancer that could not be removed by surgery or had come back after other treatments. The main goal was to see how safe the treatment was by…
Sponsor: Indiana University • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New hope for tough pancreatic cancer? early trial tests immune boosts
Disease control CompletedThis early-phase trial tested different combinations of immunotherapy drugs with standard chemotherapy for people with metastatic pancreatic cancer that had not been treated before. The main goal was to check safety and see if the combinations could shrink tumors or control the d…
Phase 1 • Sponsor: Cancer Insight, LLC • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
App helps young cancer survivors shed pounds
Disease control CompletedThis study tested a smartphone app to help young adult cancer survivors (ages 18-39) lose weight. The app tracked diet and activity as part of a behavioral weight loss program. The goal was to see if this approach was practical and well-liked by participants. The study involved 6…
Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Experimental immune therapy takes aim at pancreatic cancer
Disease control CompletedThis study tested a new experimental therapy using special immune cells (T cells) trained to attack proteins found on pancreatic cancer cells. The trial included 37 patients whose cancer had returned or not responded to standard treatment, or who chose not to have chemotherapy. T…
Phase 1/2 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New immunotherapy DF9001 targets Hard-to-Treat cancers
Disease control CompletedThis study tested a new drug called DF9001, which helps the body's natural killer cells attack cancer cells. It was given alone or with another immunotherapy (pembrolizumab) to 24 adults with advanced solid tumors that have the EGFR protein. The goal was to check safety and find …
Phase 1/2 • Sponsor: Dragonfly Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New combo therapy shows promise in early cancer trial
Disease control CompletedThis early-phase study tested an experimental drug (MK-1454) injected directly into tumors, either alone or with pembrolizumab (Keytruda), in 156 people with advanced solid tumors or lymphomas. The main goals were to find the safest dose and check for side effects. The study also…
Phase 1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New drug combo targets Hard-to-Treat cancers
Disease control CompletedThis study tested a new oral drug called RP-3500 (camonsertib), alone or combined with talazoparib or gemcitabine, in 276 adults with advanced solid tumors that have certain genetic mutations. The main goals were to find the safest dose and check for early signs of tumor shrinkag…
Phase 1/2 • Sponsor: Repare Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Which antibiotic wins? study tests infection prevention in pancreatic surgery
Disease control CompletedThis study looked at nearly 1,000 adults having pancreatic surgery to see which antibiotic, cefoxitin or piperacillin-tazobactam, works better at preventing wound infections within 30 days after the operation. Participants received one of the two antibiotics before surgery. The g…
Phase 3 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New drug cocktail shows promise in Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested two drugs—sapanisertib and ziv-aflibercept—in 83 people with advanced solid tumors that had spread or could not be removed. The goal was to find the safest dose and check for side effects. Sapanisertib blocks enzymes that help cancer cells grow, whil…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New antibody combo tested in advanced cancer patients
Disease control CompletedThis early-phase trial tested a new antibody drug called AGEN1777, given alone or with another antibody (a PD-1 inhibitor), in 25 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the right dose, and se…
Phase 1 • Sponsor: Agenus Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Experimental drug duo targets Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested a combination of two experimental drugs, vobramitamab duocarmazine and lorigerlimab, in 31 people with advanced solid tumors like prostate, melanoma, and pancreatic cancer. The main goal was to check safety and find the right dose. Participants recei…
Phase 1 • Sponsor: MacroGenics • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New cocktail aims to stall pancreatic cancer after chemo
Disease control CompletedThis study tested whether adding an immunotherapy drug (ipilimumab or nivolumab) to niraparib, a targeted therapy, can prevent advanced pancreatic cancer from growing. It enrolled 104 adults whose cancer had not worsened after platinum-based chemotherapy. The goal was to see how …
Phase 1/2 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New drug combo shows promise in early trial for advanced cancers
Disease control CompletedThis early-phase study tested an experimental drug called MK-4830, either by itself or combined with other cancer therapies like pembrolizumab, in 470 people with advanced solid tumors. The main goals were to check safety, find the right dose, and see if tumors shrank. The study …
Phase 1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New drug AMG 256 tested in patients with hard-to-treat cancers
Disease control CompletedThis early-phase study tested a new drug called AMG 256 in 34 adults with advanced solid tumors that could not be cured by standard treatments. The main goals were to check the drug's safety and find the best dose for future studies. Researchers monitored side effects and how the…
Phase 1 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Proton beam zaps liver tumors: new hope for cancer patients?
Disease control CompletedThis study tested a precise type of radiation called proton beam therapy for people whose cancer has spread to the liver. 92 adults with 1 to 4 liver tumors received this treatment. The goal was to see if it could stop tumor growth and cause fewer side effects than standard radia…
Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New cancer drug shows early promise in small safety trial
Disease control CompletedThis early-phase trial tested a new drug called BI 836880 in 29 adults with advanced solid tumors that had not responded to standard treatments. The main goal was to find a safe dose and check for side effects. The study was not designed to cure cancer, but to gather information …
Phase 1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New combo therapy shows promise in tough pancreatic cancer
Disease control CompletedThis study tested a new treatment plan for people with advanced pancreatic cancer that has spread. It combined chemotherapy with drugs that change how genes work and boost the immune system. The goal was to see if this approach is safe and can help control the disease. 75 patient…
Phase 1/2 • Sponsor: GWT-TUD GmbH • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New cancer cocktail shows promise in early human trial
Disease control CompletedThis early-phase study tested an experimental drug called ABBV-CLS-579, given alone or with other cancer treatments, in 101 adults with advanced solid tumors that had stopped responding to standard therapy. The main goal was to find safe and tolerable doses, not to prove the drug…
Phase 1 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Triple-Drug cocktail shows promise in Hard-to-Treat cancers
Disease control CompletedThis early-phase study tested a combination of three drugs—selinexor, nivolumab, and ipilimumab—in 11 adults with advanced or metastatic solid tumors that had stopped responding to standard treatments. The main goal was to check the safety and tolerability of the combination, whi…
Phase 1 • Sponsor: National University Hospital, Singapore • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New combo therapy targets Hard-to-Treat tumors
Disease control CompletedThis early-phase trial tested a new drug called RiMO-301, injected directly into tumors, along with standard radiation. It involved 32 people with advanced cancers that could not be cured. The main goal was to find a safe dose and check for any early signs of tumor shrinkage.
Phase 1 • Sponsor: Coordination Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 26, 2026 17:16 UTC
-
New pill plus immunotherapy shows promise in early cancer trial
Disease control CompletedThis early-phase study tested an experimental drug called TPST-1495, taken as a pill, either alone or combined with the immunotherapy Keytruda (pembrolizumab). The trial included 89 people with advanced solid tumors like colorectal, lung, head and neck, and endometrial cancers wh…
Phase 1 • Sponsor: Tempest Therapeutics • Aim: Disease control
Last updated Jun 26, 2026 15:48 UTC
-
Pancreatic cancer radiation gets a boost: safety trial tests higher doses
Disease control CompletedThis completed phase I trial tested whether higher doses of a precise type of radiation called stereotactic body radiotherapy (SBRT) are safe for people with pancreatic cancer. Thirty patients with inoperable or locally advanced pancreatic cancer received five targeted radiation …
Sponsor: University of California, San Diego • Aim: Disease control
Last updated Jun 26, 2026 15:26 UTC
-
Experimental Vaccine-Like therapy targets Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested an experimental immunotherapy called ELI-002 in 25 people with KRAS-mutated pancreatic, colorectal, lung, ovarian, or bile duct cancers who had signs of remaining disease after standard treatment. The therapy aims to train the immune system to attack…
Phase 1 • Sponsor: Elicio Therapeutics • Aim: Disease control
Last updated Jun 26, 2026 13:30 UTC
-
Experimental cancer drug PTX-100 enters early human testing
Disease control CompletedThis early-phase trial tested a new drug called PTX-100 in 25 people with advanced cancers like multiple myeloma, lymphoma, and certain solid tumors. The goal was to find safe doses and understand how the drug behaves in the body. Participants received the drug by IV for five day…
Phase 1 • Sponsor: Prescient Therapeutics, Ltd. • Aim: Disease control
Last updated Jun 26, 2026 12:35 UTC
-
A watchful eye: could alternating scans outsmart pancreatic cancer?
Diagnosis CompletedThis study follows people with a significantly elevated risk of pancreatic cancer—due to inherited gene mutations or strong family history—who choose to undergo early detection testing. Participants receive endoscopic ultrasound (EUS) and MRI scans on an alternating schedule ever…
Sponsor: White Plains Hospital • Aim: Diagnosis
Last updated Aug 27, 2026 00:00 UTC
-
Can a new biopsy needle unlock personalized pancreatic cancer therapy?
Diagnosis CompletedThis trial evaluates a new biopsy needle (Micro-Tech FNB) used during endoscopic ultrasound to collect tissue samples from suspected pancreatic tumors. The goal is to see if this needle provides accurate diagnoses and yields enough high-quality tissue for genetic sequencing, whic…
Sponsor: Radboud University Medical Center • Aim: Diagnosis
Last updated Aug 23, 2026 00:00 UTC
-
Can sound waves reveal pancreatic cancer without a biopsy?
Diagnosis CompletedThis trial is evaluating whether a specialized ultrasound technique, called shear wave elastography, can accurately identify pancreatic cancer. The study will include 130 adults with a solid pancreatic mass of unknown cause. By measuring tissue stiffness, the technique may help d…
Sponsor: GCS Ramsay Santé pour l'Enseignement et la Recherche • Aim: Diagnosis
Last updated Aug 22, 2026 00:00 UTC
-
Sound waves may spot nerve harm in cancer patients
Diagnosis CompletedThis pilot study tested whether ultrasound can detect nerve damage caused by the chemotherapy drug oxaliplatin in people with gastrointestinal cancer. Twenty participants who had or were receiving oxaliplatin and had symptoms of nerve damage underwent nerve ultrasounds, skin biop…
Sponsor: Wake Forest University Health Sciences • Aim: Diagnosis
Last updated Jul 23, 2026 00:00 UTC
-
New scan could reveal hidden cancer cells
Diagnosis CompletedThis early study tested a radioactive imaging agent called [99mTc]Tc(CO)3-(HE)3-Ec1 in 10 adults with solid tumors. The agent is designed to attach to EpCAM receptors on cancer cells, making them visible on SPECT scans. Researchers aimed to see where the agent goes in the body, m…
Phase 1 • Sponsor: Tomsk National Research Medical Center of the Russian Academy of Sciences • Aim: Diagnosis
Last updated Jun 27, 2026 14:03 UTC
-
New imaging agent targets LRRC15 to sharpen cancer diagnosis
Diagnosis CompletedThis study tests a special SPECT imaging agent that seeks out a protein called LRRC15, found on many aggressive cancers like pancreatic, breast, lung, and brain tumors. The goal is to see if this scan can help doctors diagnose and stage these cancers more accurately. Healthy volu…
Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Diagnosis
Last updated Jun 27, 2026 14:00 UTC
-
New scan spots hidden oxygen shortage in pancreatic tumors
Diagnosis CompletedThis study tested whether a PET scan using a tracer called 18F-FAZA can measure low oxygen levels (hypoxia) in pancreatic cancer. Hypoxia can affect how the cancer grows and responds to treatment. 48 adults with pancreatic cancer received the scan, and researchers also collected …
Sponsor: University Health Network, Toronto • Aim: Diagnosis
Last updated Jun 27, 2026 13:07 UTC
-
New scan lights up hidden gut tumors
Diagnosis CompletedThis completed Phase 3 trial tested a special PET-CT scan using a radioactive tracer called gallium-68 DOTATOC to find neuroendocrine tumors in the stomach, intestines, and pancreas. 69 adults with confirmed or suspected tumors received the scan. The goal was to see how accuratel…
Phase 3 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Diagnosis
Last updated Jun 27, 2026 13:07 UTC
-
New imaging agent could sharpen pancreatic cancer detection
Diagnosis CompletedThis study tested a radioactive tracer called [68Ga]FAPI-46, used with a PET scan, to see if it can better detect pancreatic cancer cells. 63 adults with early-stage pancreatic cancer received the tracer before surgery. The goal was to see how well the scan matches the actual can…
Phase 2 • Sponsor: SOFIE • Aim: Diagnosis
Last updated Jun 27, 2026 13:00 UTC
-
Could a new PET scan help match pancreatic cancer patients to the right therapy?
Diagnosis CompletedThis phase 1 trial tested a new radioactive imaging agent called 64Cu-DOTA-ECL1i to see if it can detect a protein called CCR2 in pancreatic tumors using PET scans. The study involved 69 adults with pancreatic ductal adenocarcinoma at various stages. The goal was to see if the sc…
Phase 1 • Sponsor: Washington University School of Medicine • Aim: Diagnosis
Last updated Jun 27, 2026 12:30 UTC
-
New ultrasound technique could reveal hidden cancer spread in pancreatic patients
Diagnosis CompletedThis study looked at whether a special ultrasound done before surgery can find small cancer spots that have spread from the main pancreatic tumor. Doctors used an endoscopic ultrasound to check lymph nodes near and far from the tumor. The goal was to see if this method could impr…
Sponsor: IHU Strasbourg • Aim: Diagnosis
Last updated Jun 27, 2026 12:08 UTC
-
New blood test spots silent liver metastases in pancreatic cancer patients
Diagnosis CompletedThis study tested a new blood test that looks for tiny particles (exosomes) released by cancer cells to find early liver spread in people with pancreatic cancer before they have surgery. The goal is to help doctors decide the best treatment plan by identifying patients at high ri…
Sponsor: City of Hope Medical Center • Aim: Diagnosis
Last updated Jun 27, 2026 11:01 UTC
-
New study aims to spot which pancreatic cysts turn cancerous
Diagnosis CompletedThis study looked at 477 adults with pancreatic cysts to find better ways to tell which cysts are harmless and which might become cancer. Researchers combined medical images, patient history, and fluid from the cysts to create a more accurate prediction model. The goal is to help…
Sponsor: Johns Hopkins University • Aim: Diagnosis
Last updated Jun 27, 2026 09:09 UTC
-
New blood and urine tests could spot Drug-Related pancreatitis early
Diagnosis CompletedThis study looked at new markers in blood and urine to detect and predict the severity of drug-associated acute pancreatitis in adults. Researchers compared these markers in 175 patients with drug-induced pancreatitis, other pancreatic diseases, and healthy volunteers. The goal i…
Sponsor: University of Liverpool • Aim: Diagnosis
Last updated Jun 27, 2026 09:06 UTC
-
New PET tracer could sharpen cancer detection
Diagnosis CompletedThis study tested a new radioactive tracer called [18F]FAPI-74 for PET scans in people with gastrointestinal cancers, including liver, bile duct, stomach, pancreatic, and colorectal cancers. The goal was to see if the tracer can accurately detect cancer cells by comparing scan re…
Phase 2 • Sponsor: SOFIE • Aim: Diagnosis
Last updated Jun 27, 2026 08:13 UTC
-
New PET scan tracer could shine a light on hidden pancreatic tumors
Diagnosis CompletedThis study tested a new radioactive tracer called 18F-Exendin-4, used with PET/CT scans, to see if it can better detect insulinoma—a rare tumor in the pancreas that causes dangerously low blood sugar. Twenty participants with confirmed insulinoma received the tracer and underwent…
Sponsor: Sichuan Provincial People's Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 08:11 UTC
-
Artificial intelligence reads CT scans to forecast pancreatic cancer prognosis
Diagnosis CompletedThis study used artificial intelligence to analyze CT scans and tissue samples from 247 pancreatic cancer patients. The goal was to create a model that predicts how the cancer will behave and how well patients will respond to chemotherapy. The model showed promising accuracy, but…
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Diagnosis
Last updated Jun 27, 2026 08:09 UTC
-
New PET tracer aims to light up hidden infections
Diagnosis CompletedThis early study tested a new radioactive tracer called 18F-FDS in 16 people with suspected bacterial or fungal infections. The tracer is designed to light up infection sites on PET/CT scans, helping doctors see exactly where an infection is. The goal was to check how the tracer …
Sponsor: Johns Hopkins University • Aim: Diagnosis
Last updated Jun 27, 2026 08:03 UTC
-
Can a pill shield ears from chemo damage?
Prevention CompletedThis study tests whether the drug SENS-401 can prevent hearing loss caused by cisplatin, a common chemotherapy. Adults with cancer who are scheduled to receive cisplatin take SENS-401 before, during, and after treatment. Hearing is measured with a standard test to see if the drug…
Phase 2 • Sponsor: Sensorion • Aim: Prevention
Last updated Jul 04, 2026 00:00 UTC
-
New catheter lock could slash infection risk for cancer patients
Prevention CompletedThis study tested whether a taurolidine-citrate solution (TauroLock) placed in the catheter between treatments can prevent bloodstream infections in adults with solid tumors receiving IV anti-cancer therapy. 162 patients were randomly assigned to get either the TauroLock solution…
Sponsor: Centre Hospitalier Régional Metz-Thionville • Aim: Prevention
Last updated Jun 27, 2026 14:02 UTC
-
Heartburn drug may shield cancer patients from nerve pain
Prevention CompletedThis study tested whether omeprazole, a common heartburn medication, could prevent nerve damage caused by oxaliplatin chemotherapy in 46 adults with colorectal or pancreatic cancer. Participants took omeprazole before and during chemotherapy cycles. The goal was to see if it redu…
Phase 3 • Sponsor: Aya Mohamed Sadek Elsaid • Aim: Prevention
Last updated Jun 26, 2026 15:11 UTC
-
Lower dose of olanzapine may ease chemo nausea with less drowsiness
Symptom relief CompletedThis study looked at 2,000 adults with solid tumors to find the best dose of olanzapine for preventing nausea and vomiting caused by strong chemotherapy. Researchers compared 2.5 mg, 5 mg, and 10 mg doses to see which works best with the fewest side effects like daytime sleepines…
Sponsor: Shandong Cancer Hospital and Institute • Aim: Symptom relief
Last updated Sep 11, 2026 00:00 UTC
-
Ear zaps may Kick-Start stomach after pancreatic surgery
Symptom relief CompletedThis study tested whether a device that gently stimulates the vagus nerve through the ear could reduce delayed stomach emptying after a major pancreatic surgery (pancreaticoduodenectomy). 84 patients were randomly assigned to receive the stimulation during surgery or not. The goa…
Sponsor: Affiliated Hospital of Nantong University • Aim: Symptom relief
Last updated Sep 03, 2026 00:00 UTC
-
Can an AI chatbot lift the spirits of advanced cancer patients?
Symptom relief CompletedThis trial tests whether an AI emotional companion app can improve depression, anxiety, and demoralization in adults with advanced cancer. Participants use a mobile app where a virtual character holds conversations, reads emotional cues, and offers a link to a human hotline if di…
Sponsor: National Yang Ming Chiao Tung University • Aim: Symptom relief
Last updated Aug 30, 2026 00:00 UTC
-
A card game could open the door to better End-of-Life conversations
Symptom relief CompletedThis study tests whether a conversation game called 'Hello' can help people with cancer and their loved ones discuss advance care planning—decisions about future medical care. Participants will play either the Hello game or a similar conversation game, complete questionnaires, an…
Sponsor: Milton S. Hershey Medical Center • Aim: Symptom relief
Last updated Aug 23, 2026 00:00 UTC
-
Can light therapy unblock a common cancer side effect?
Symptom relief CompletedThis trial tests whether laser acupuncture, a non-invasive therapy using low-intensity light on traditional acupoints, can relieve constipation in people with advanced cancer. Participants are adults with advanced cancer who have constipation despite using laxatives. The study me…
Sponsor: Chang Gung Memorial Hospital • Aim: Symptom relief
Last updated Aug 22, 2026 00:00 UTC
-
Magic mushroom compound tested for cancer anxiety
Symptom relief CompletedThis early-stage study tests whether a single dose of psilocybin, the active ingredient in magic mushrooms, can reduce depression and anxiety in people with advanced pancreatic, biliary, or other gastrointestinal cancers. The study enrolls 24 adults aged 19-85 with stage IV or in…
Phase 1 • Sponsor: University of Nebraska • Aim: Symptom relief
Last updated Aug 21, 2026 00:00 UTC
-
Peppermint and lemon scents put to the test against chemo nausea
Symptom relief CompletedThis phase 2 trial tests whether inhaling a blend of peppermint and lemon essential oils can reduce nausea and vomiting in people receiving their first chemotherapy for a solid tumor. Participants will inhale the oils four times daily and whenever nausea strikes, with symptoms tr…
Phase 2 • Sponsor: Centre Francois Baclesse • Aim: Symptom relief
Last updated Aug 19, 2026 00:00 UTC
-
Can a targeted nerve block outsmart pancreatic cancer pain?
Symptom relief CompletedThis trial tests whether an ultrasound-guided injection of alcohol and a numbing agent around the celiac ganglia can relieve pain in people newly diagnosed with inoperable pancreatic cancer. Participants receive either the nerve block or a sham procedure, alongside standard pain …
Phase 3 • Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) • Aim: Symptom relief
Last updated Aug 16, 2026 00:00 UTC
-
Could a low dose of ketamine ease anxiety in pancreatic cancer?
Symptom relief CompletedThis study tests whether a low dose of oral ketamine can safely help with anxiety in people with pancreatic cancer. Twenty participants will receive both ketamine and a placebo at different times to compare effects. The main goal is to see if such a study is even possible, not to…
Early phase 1 • Sponsor: Cedars-Sinai Medical Center • Aim: Symptom relief
Last updated Aug 15, 2026 00:00 UTC
-
A digital lifeline: could Real-Time symptom tracking transform care for kids with advanced cancer?
Symptom relief CompletedThis trial tests whether a new care approach, called PediQUEST Response, can improve quality of life for children, adolescents, and young adults with advanced cancer. Participants use an app to regularly report symptoms and quality of life, and a palliative care team receives the…
Sponsor: Joanne Wolfe, MD, MPH • Aim: Symptom relief
Last updated Aug 09, 2026 00:00 UTC
-
Virtual reality goggles could ease cancer Patients' procedure fears
Symptom relief CompletedThis study tests whether using a virtual reality headset during PICC line placement can reduce anxiety and pain in cancer patients. About 120 adults will be randomly assigned to either receive VR plus standard care or standard care alone. The goal is to see if this non-drug appro…
Sponsor: Istituto Oncologico Veneto IRCCS • Aim: Symptom relief
Last updated Aug 06, 2026 00:00 UTC
-
Can talking it out ease PTSD in cancer patients during a pandemic?
Symptom relief CompletedThis study tested whether monthly 45-minute psychological interviews over 6 months could reduce post-traumatic stress symptoms in cancer patients affected by the COVID-19 pandemic. It included 29 adults with solid tumors who had moderate to high PTSD symptoms. The goal was to see…
Sponsor: Centre Francois Baclesse • Aim: Symptom relief
Last updated Aug 02, 2026 00:00 UTC
-
Can a dietician and fitbit help pancreatic cancer patients feel better during chemo?
Symptom relief CompletedThis study tests a program called STRONG that gives pancreatic cancer patients extra support from a dietician and a Fitbit to track their food intake. The goal is to see if patients find the program helpful and easy to stick with while they are on chemotherapy. About 80 adults wi…
Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Symptom relief
Last updated Aug 01, 2026 00:00 UTC
-
Smart patch could spot chemo side effects before they become dangerous
Symptom relief CompletedThis trial tests whether a wearable sensor called the Alio Smart Patch can help catch early signs of febrile neutropenia, a serious infection risk from chemotherapy. Thirty adults with certain cancers will wear the patch and a glucose monitor at home, with a remote care team watc…
Sponsor: Case Comprehensive Cancer Center • Aim: Symptom relief
Last updated Jul 26, 2026 00:00 UTC
-
Smart home monitoring could help pancreatic cancer patients avoid hospital stays
Symptom relief CompletedThis study tested a home monitoring system for people with advanced pancreatic cancer receiving a strong chemotherapy called mFOLFIRINOX. The system tracked symptoms, activity, sleep, and weight using connected devices and an online platform. The goal was to see if early alerts c…
Sponsor: GCS Ramsay Santé pour l'Enseignement et la Recherche • Aim: Symptom relief
Last updated Jul 18, 2026 00:00 UTC
-
Could tiny needles tame Chemo's Gut-Wrenching side effect in kids?
Symptom relief CompletedThis study tests whether acupuncture using tiny, semi-permanent needles can prevent diarrhea caused by the chemotherapy drug irinotecan in children with solid tumors. About 22 children will receive the acupuncture during their second round of chemo, and researchers will measure p…
Sponsor: Fundació Sant Joan de Déu • Aim: Symptom relief
Last updated Jul 11, 2026 00:00 UTC
-
New drug may ease severe skin rashes in cancer patients
Symptom relief CompletedThis study tested whether the drug benralizumab can safely reduce skin rashes caused by cancer treatments like checkpoint inhibitors. The goal was to lower the number of high-grade rashes to milder ones, which could improve quality of life and help patients stay on their cancer t…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 13:01 UTC
-
New drug targets wasting syndrome in cancer patients
Symptom relief CompletedThis study tested an investigational drug called ponsegromab in 187 adults with lung, pancreatic, or colorectal cancer who also had cachexia—a condition causing severe weight loss, loss of appetite, and fatigue. The goal was to see if ponsegromab could help patients gain weight a…
Phase 2 • Sponsor: Pfizer • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
Cooling caps may keep hair on during pancreatic cancer chemo
Symptom relief CompletedThis pilot study tested a scalp cooling device (Paxman) to prevent hair loss in 9 people with advanced pancreatic cancer receiving chemotherapy. The goal was to see if the cap could keep hair loss mild (less than 50% hair loss) and improve comfort. Results focused on hair preserv…
Sponsor: HonorHealth Research Institute • Aim: Symptom relief
Last updated Jun 27, 2026 12:38 UTC
-
Silkworm pupa tablets tested to fight frailty after cancer surgery
Symptom relief CompletedThis study tested whether silkworm pupa tablets can improve nutrition and reduce frailty in people who had surgery for stomach, colorectal, esophageal, or pancreatic cancer. 120 participants took the tablets for 3 months. Researchers measured weight, frailty, muscle mass, and qua…
Sponsor: Xiaosun Liu, MD • Aim: Symptom relief
Last updated Jun 27, 2026 12:38 UTC
-
New pain coping program helps advanced cancer patients regain daily life
Symptom relief CompletedThis study tested a special pain coping skills program for people with advanced solid tumor cancer who have pain that interferes with daily activities. 211 patients were randomly assigned to either the program or standard care. The program taught ways to manage pain and find mean…
Sponsor: Duke University • Aim: Symptom relief
Last updated Jun 27, 2026 12:31 UTC
-
New heat treatment may cut cancer pain without extra drugs
Symptom relief CompletedThis study tested a procedure called endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) to treat pain in 19 people with advanced pancreatic cancer that could not be removed by surgery. The goal was to see if zapping the celiac ganglion—a bundle of nerves—could reduce …
Sponsor: West Virginia University • Aim: Symptom relief
Last updated Jun 27, 2026 12:24 UTC
-
Mindfulness may ease stress for liver patients
Symptom relief CompletedThis study looked at whether mindfulness exercises can lower stress and improve communication between patients with liver disease and their doctors. 56 adults took part, answering surveys about their stress, anxiety, and how well they felt they could share decisions with their he…
Sponsor: Methodist Health System • Aim: Symptom relief
Last updated Jun 27, 2026 12:00 UTC
-
Can a digital coach help pancreatic cancer patients? small study tests feasibility
Symptom relief CompletedThis pilot study tested a 12-week digital health coaching program for people with pancreatic cancer and their caregivers. The program included coaching sessions by phone, text, or email to help manage symptoms. The study aimed to see if the program was easy to use and if particip…
Early phase 1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Symptom relief
Last updated Jun 27, 2026 09:03 UTC
-
Can acupuncture and ice chips beat chemo nerve damage?
Symptom relief CompletedThis phase 2 trial looked at whether adding acupuncture and acupressure to oral cryotherapy (sucking on ice chips) can reduce nerve pain caused by oxaliplatin chemotherapy in people with gastrointestinal cancers. 78 patients were split into two groups: one got cryotherapy alone, …
Phase 2 • Sponsor: University of Washington • Aim: Symptom relief
Last updated Jun 27, 2026 08:13 UTC
-
Could a common cholesterol drug protect cancer Patients' hearing?
Symptom relief CompletedThis study looked at whether taking statins (cholesterol-lowering drugs) can reduce hearing loss caused by platinum-based chemotherapy in people with solid tumors. 56 adults who were about to start chemotherapy took part. The goal was to see if statins could protect their ears fr…
Phase 1/2 • Sponsor: Minia University • Aim: Symptom relief
Last updated Jun 27, 2026 08:13 UTC
-
Talking through cancer: can couples therapy ease the emotional toll?
Symptom relief CompletedThis study tested a program that teaches couples communication skills when one partner has advanced cancer. About 440 patients and their partners took part, with half receiving the training and half getting general healthy living information. The goal was to see if the training c…
Sponsor: Duke University • Aim: Symptom relief
Last updated Jun 27, 2026 08:13 UTC
-
Shea butter and niacinamide cream may ease itching for immunotherapy patients
Symptom relief CompletedThis study tested whether using creams with niacinamide and shea butter can prevent or reduce skin itching in cancer patients receiving immunotherapy. 130 adults with solid tumors starting checkpoint inhibitor treatment were randomly assigned to use either the test cream or a con…
Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau • Aim: Symptom relief
Last updated Jun 27, 2026 08:10 UTC
-
Can a palliative care team boost quality of life for cancer surgery patients?
Symptom relief CompletedThis study looked at whether having a palliative care team work alongside surgeons improves quality of life for patients with gastrointestinal cancers like pancreatic or liver cancer. About 379 patients and their family members took part. The main goal was to see if this team app…
Sponsor: Stanford University • Aim: Symptom relief
Last updated Jun 27, 2026 08:09 UTC
-
Extra nerve block helps pancreatic surgery patients leave hospital without opioids
Symptom relief CompletedThis study looked at whether giving an additional anesthetic nerve block after pancreatic surgery helps patients use fewer opioid painkillers. 136 adults having open pancreatic surgery for cancer were randomly assigned to receive either one nerve block or a repeat block. The main…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 08:06 UTC
-
Weight-Loss drug shows promise for pancreatic cancer patients
Symptom relief CompletedThis study tested a drug called telotristat ethyl in 23 people with advanced pancreatic cancer who had lost at least 10% of their body weight. The goal was to see if the drug could help them stabilize or gain weight by reducing bowel movements. Maintaining weight may help patient…
Phase 2 • Sponsor: Emory University • Aim: Symptom relief
Last updated Jun 27, 2026 08:04 UTC
-
Stent procedure eases severe symptoms in cancer patients with blocked veins
Symptom relief CompletedThis study looked at placing a small metal tube (stent) into the portal vein of 63 cancer patients whose vein was blocked by a tumor. The goal was to relieve serious symptoms like fluid buildup in the belly or bleeding in the gut. The procedure was done through a needle in the li…
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Symptom relief
Last updated Jun 27, 2026 08:00 UTC
-
Can reiki ease cancer pain? small study says maybe
Symptom relief CompletedThis study tested whether Reiki, a relaxation therapy where a practitioner places hands on or near the body, could help cancer patients with symptoms like pain and fatigue. Ten adults with cancer who had at least three bothersome symptoms received up to six Reiki sessions. Resear…
Sponsor: Case Comprehensive Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 07:56 UTC
-
New online program eases Kids' cancer return to school
Symptom relief CompletedThis study tested a web-based program to help children aged 8-17 with cancer adjust to returning to school. The program included modules for children, parents, teachers, and peers, focusing on communication, coping, and social skills. Twenty children participated, and researchers…
Sponsor: Gazi University • Aim: Symptom relief
Last updated Jun 27, 2026 07:52 UTC
-
New study tests monthly day care for advanced cancer patients
Symptom relief CompletedThis study looked at whether monthly visits to a hospital day care that includes palliative care can improve quality of life for adults with advanced cancer. 144 patients with a life expectancy between 2 and 12 months took part. Researchers measured changes in quality of life, fa…
Sponsor: Institut Curie • Aim: Symptom relief
Last updated Jun 26, 2026 18:50 UTC
-
AI learns to catch early gut cancers in endoscopy videos
Knowledge-focused CompletedThis study collects videos and images from 1,650 adults having a camera test of their stomach or bowel (endoscopy). Researchers will use these recordings to see how well artificial intelligence (AI) can spot early signs of cancer. The goal is to improve detection and help doctors…
Sponsor: Portsmouth Hospitals NHS Trust • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Immunotherapy side effects under the microscope: MOTIVATE study tracks 150 patients
Knowledge-focused CompletedThis study followed 150 people with solid tumors who were starting immunotherapy (immune checkpoint inhibitors) as part of their regular care. Researchers collected data on side effects and asked patients to fill out questionnaires before each treatment. The goal was to better un…
Sponsor: Institut Claudius Regaud • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Should all young cancer patients get genetic testing? study investigates
Knowledge-focused CompletedThis study looked at whether offering genetic testing to all young adults with cancer (ages 18-39) is better than only testing those who meet certain guidelines. About 749 participants were randomly assigned to either universal testing with a broad gene panel or standard testing …
Sponsor: University of Pennsylvania • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Robotic surgery vs standard approaches: does the platform change cancer outcomes?
Knowledge-focused CompletedResearchers at a large hospital in Seoul reviewed records from nearly 33,000 adults who had curative-intent surgery for one of seven cancers in the abdomen or pelvis: pancreatic, gastric, rectal, cervical, endometrial, kidney, or prostate. They grouped patients by whether they re…
Sponsor: Asan Medical Center • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Mining Responders' tumors for clues to a universal cancer therapy
Knowledge-focused CompletedResearchers want to learn which molecules on cancer cells the immune system attacks when checkpoint inhibitor drugs work well. They collect tumor and blood samples from adults with solid tumors who respond to these drugs, either during treatment or after surgery. The team then se…
Sponsor: TScan Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
Glow-in-the-dark dye may help surgeons spot hidden cancer in kids
Knowledge-focused CompletedThis study is testing whether a green dye called ICG can help surgeons see tumors more clearly during surgery in children and teens with solid tumors. The dye is injected before surgery and makes tumor tissue glow under a special camera. The goal is to see if this technique helps…
Phase 1 • Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC
-
Can the mediterranean diet survive chemo? new study investigates
Knowledge-focused CompletedThis study looked at how cancer treatment changes patients' ability to stick with a Mediterranean diet. Researchers followed 116 patients starting chemotherapy or immunotherapy, checking their diet adherence and sensory changes (taste and smell) at the start and after 9 weeks. Th…
Sponsor: Centre Antoine Lacassagne • Aim: Knowledge-focused
Last updated Aug 28, 2026 00:00 UTC
-
New ultrasound test may predict dangerous pancreatic leaks after surgery
Knowledge-focused CompletedThis study is testing whether a special type of ultrasound, called endoscopic ultrasound elastography, can predict the texture of the pancreas and the risk of a pancreatic fistula after a major surgery called pancreaticoduodenectomy. The study will enroll 100 adults scheduled for…
Sponsor: Minia University • Aim: Knowledge-focused
Last updated Aug 20, 2026 00:00 UTC
-
A 5-minute quiz might predict who gets severe chemo side effects
Knowledge-focused CompletedThis study looks at whether a short risk-assessment tool, called the CARG score, can predict severe side effects from chemotherapy in cancer patients aged 70 and older. Participants will answer questions about their health and daily function before starting a new chemotherapy reg…
Sponsor: RenJi Hospital • Aim: Knowledge-focused
Last updated Aug 20, 2026 00:00 UTC
-
Michigan study tests ways to boost genetic testing in cancer patients
Knowledge-focused CompletedThis study looked at whether a special website or coaching phone calls could help more people with a personal or family history of certain cancers get genetic testing. Over 800 participants were randomly assigned to one of these two methods or to standard care. The goal was to se…
Sponsor: University of Michigan Rogel Cancer Center • Aim: Knowledge-focused
Last updated Aug 20, 2026 00:00 UTC
-
Blood test may spare cancer patients unneeded iron infusions
Knowledge-focused CompletedThis trial explores whether a blood test measuring reticulocyte hemoglobin content (RET-He) can predict how well cancer patients with anemia will respond to intravenous iron treatment. The study involves adults with solid tumors who have functional iron deficiency. By checking RE…
Sponsor: Institut Cancerologie de l'Ouest • Aim: Knowledge-focused
Last updated Aug 19, 2026 00:00 UTC
-
Cancer clot care under the microscope: new study mines data for better treatment insights
Knowledge-focused CompletedThis study reviews existing medical records to understand how blood clots (VTE) are treated in people with active cancer or a history of cancer. Researchers will look at which blood thinners are used, how often clots come back, and the costs involved. No new treatments are given—…
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Jul 26, 2026 00:00 UTC
-
ECMO in kids with cancer: a closer look at survival and risks
Knowledge-focused CompletedThis study examines how children under 18 with cancer or a history of a stem cell transplant do when they need a machine called ECMO to help them breathe. Researchers looked at bleeding, infections, and survival rates in children treated at one hospital, and compared survival wit…
Sponsor: Children's Mercy Hospital Kansas City • Aim: Knowledge-focused
Last updated Jul 22, 2026 00:00 UTC
-
Ultrasound inside the body reveals how tumors block the bile duct
Knowledge-focused CompletedThis study uses endoscopic ultrasound—a tiny ultrasound probe on a flexible tube passed through the mouth—to measure the size of the common bile duct in people with jaundice caused by pancreatic or bile duct tumors. Researchers aim to better understand how these tumors compress t…
Sponsor: GCS Ramsay Santé pour l'Enseignement et la Recherche • Aim: Knowledge-focused
Last updated Jul 18, 2026 00:00 UTC
-
Oxygen mapping in pancreatic tumors could reveal hidden clues to aggressive cancer
Knowledge-focused CompletedThis study investigates low-oxygen (hypoxic) areas within pancreatic tumors by giving patients a special marker before surgery. The marker highlights oxygen-deprived regions in the removed tumor tissue. Researchers will then analyze how these hypoxic zones relate to patient survi…
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jul 12, 2026 00:00 UTC
-
New risk score aims to predict which pancreatic tumors will return after surgery
Knowledge-focused CompletedThis study aims to create a simple risk score to identify patients with pancreatic neuroendocrine tumors (PanNETs) who are at high risk of their cancer returning after surgery. Current methods are not very good at predicting individual risk. Researchers will analyze data from ove…
Sponsor: Fudan University • Aim: Knowledge-focused
Last updated Jul 12, 2026 00:00 UTC
-
Can a quick chat with a radiotherapy tech ease cancer patients' anxiety?
Knowledge-focused CompletedThis study looked at whether having a special consultation with a radiotherapy technician (called a manipulator) helps cancer patients feel more informed about their treatment. Researchers enrolled 308 adults with various cancers who were getting radiation therapy. They compared …
Sponsor: Centre Antoine Lacassagne • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Can a Child's cancer be inherited? new study digs into family DNA
Knowledge-focused CompletedThis study looks at the DNA of 100 children (and young adults up to age 17) who have cancer, along with the DNA of their healthy parents. The goal is to find genetic changes that may have caused the cancer. By comparing the child's DNA to both parents', researchers hope to discov…
Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
European registry aims to improve care for pancreatic enzyme deficiency
Knowledge-focused CompletedThis study creates a registry of adults with pancreatic exocrine insufficiency (PEI), a condition where the pancreas does not produce enough enzymes to digest food properly. Researchers at eight specialist centers across Europe will track how doctors prescribe pancreatic enzyme r…
Sponsor: Hospital Clinico Universitario de Santiago • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
PET scan patients may soon be allowed to move freely during the long wait
Knowledge-focused CompletedThis study tested whether letting patients move freely between the injection of a radioactive tracer and the PET scan affects image quality. Normally, patients must rest for an hour to avoid muscle uptake that can blur results. The trial involved 284 adults with cancer or needing…
Sponsor: Centre Hospitalier Régional d'Orléans • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Can a quick GP visit improve cancer care? new study aims to find out
Knowledge-focused CompletedThis study looks at whether it's possible for people diagnosed with solid tumors to have a follow-up visit with their general practitioner within 15 days of learning their diagnosis. Researchers will track how many patients actually attend this visit and why some might not. The g…
Sponsor: Institut Claudius Regaud • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Study aims to unlock secrets of immunotherapy skin reactions
Knowledge-focused CompletedThis study observed 255 cancer patients receiving immunotherapy to understand why some develop skin side effects. Researchers measured immune markers and lipids in the skin and blood. The goal is to identify patterns that could predict or explain these reactions.
Sponsor: National Jewish Health • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Blood tests before surgery could predict complications
Knowledge-focused CompletedThis study looked at 58 patients scheduled for pancreatic surgery due to suspected cancer. Researchers collected blood samples before and after surgery to measure immune function and inflammation. They then tracked complications like low blood pressure and infections. The goal wa…
Sponsor: Rigshospitalet, Denmark • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
500 patient records reviewed to see how pancreatic cancer treatments worked
Knowledge-focused CompletedThis study reviewed medical records of 500 adults treated for benign or malignant pancreatic and stomach diseases from 2005 onward. Researchers looked at overall survival after various treatments. The goal was to understand real-world outcomes, not to test a new drug or procedure…
Sponsor: Methodist Health System • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
Study reveals why immunotherapy works differently in liver, lung, and brain tumors
Knowledge-focused CompletedThis study looked at medical records of 938 adults with solid tumors who received immunotherapy. Researchers compared how well the treatment worked when cancer had spread to different organs like the liver, brain, lung, or bone. The goal is to understand why some metastatic sites…
Sponsor: Wenlong Zhong, MD • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
Proton therapy gets a daily Tune-Up in small pilot study
Knowledge-focused CompletedThis pilot study tested whether it's possible to adjust proton radiation plans each day while the patient is on the treatment table. Ten adults with solid tumors took part. The goal was to see if this approach is safe and practical enough to study in a larger trial.
Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
Tiny blood vessel coating may hold key to better surgery monitoring
Knowledge-focused CompletedThis study looked at a thin layer inside blood vessels called the glycocalyx in 78 adults having major abdominal surgery. Researchers used a special camera to measure changes in this layer during and after surgery. The goal was to see if tracking glycocalyx thickness could help d…
Sponsor: University Hospital, Rouen • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
New website aims to close cancer care gap for black patients
Knowledge-focused CompletedThis study created and tested an educational website to help Black and African American cancer patients learn about personalized cancer treatments and clinical trials. Researchers interviewed 48 patients and caregivers, then tested the website with 33 patients. The goal was to se…
Sponsor: Rutgers, The State University of New Jersey • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
AI takes on cancer experts: who wins?
Knowledge-focused CompletedThis study looked at whether an AI computer program could suggest cancer treatments that match what experts recommend. Researchers reviewed medical records of 30 people with stomach, colon, or pancreatic cancer. They entered key details into the AI and compared its suggestions to…
Sponsor: Medizinische Hochschule Brandenburg Theodor Fontane • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
Blood tests and surveys may predict cancer treatment success
Knowledge-focused CompletedThis study followed 159 people with metastatic colorectal, pancreatic, biliary, or esophageal cancers who were starting a new line of therapy. Researchers collected blood samples (tumor markers and liquid biopsies) and patient-reported quality-of-life data to see if these could p…
Sponsor: Massachusetts General Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
Cancer surgery recovery: quality of life under the microscope
Knowledge-focused CompletedThis study tracked 295 adults who had high-risk surgery for stomach, esophagus, pancreas, or liver cancer. Researchers measured quality of life before surgery and again at 6 and 12 months after. They also asked patients and their family members if they regretted the decision to h…
Sponsor: University Hospital, Geneva • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
New study tracks fatigue and blood sugar in pancreatic tumor patients with diabetes
Knowledge-focused CompletedThis study followed 99 people who had both an operable pancreatic tumor and diabetes for one year after surgery. Researchers tracked their fatigue, blood sugar control, diabetes self-care, and quality of life to understand how these factors change over time. The goal was to learn…
Sponsor: National Taiwan University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:25 UTC
-
Scientists hunt for biomarkers in pancreatic cancer to guide therapy
Knowledge-focused CompletedThis study aimed to find biological markers (biomarkers) in pancreatic tumor cells and blood that could help predict how well a patient might respond to treatment. Researchers analyzed genetic and protein information from tumor samples collected via ultrasound-guided biopsy, as w…
Sponsor: Institut Paoli-Calmettes • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Tumor DNA test may match patients to smarter cancer drugs
Knowledge-focused CompletedThis study looked at whether analyzing the DNA of a patient's tumor can help doctors pick a targeted therapy for advanced or metastatic cancer. Researchers enrolled 550 adults with various solid tumors that had spread. They took biopsy or blood samples to search for genetic chang…
Sponsor: Institut Paoli-Calmettes • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Age alone Shouldn't decide: study suggests surgery may help fit octogenarians with pancreatic cancer
Knowledge-focused CompletedThis study looked at over 2,000 older adults (80+) with pancreatic cancer that hadn't spread, all in good general health. Researchers compared those who had surgery to remove the tumor with those who didn't, using data from a German cancer registry. The goal was to see if surgery…
Sponsor: Medizinische Hochschule Brandenburg Theodor Fontane • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Radiation before knife: small study tests new pancreatic cancer approach
Knowledge-focused CompletedThis study looked at whether giving a short, strong dose of radiation right before surgery is possible for people with pancreatic cancer. Ten patients took part to see if the approach was safe and could help surgeons remove the tumor completely. The main goal was to check for com…
Sponsor: CCTU- Cancer Theme • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:10 UTC
-
New endoscopic technique hunts cancer cells in the portal vein
Knowledge-focused CompletedThis study tested whether it is safe and possible to collect a blood sample from the portal vein (a major liver blood vessel) during a routine endoscopic ultrasound in 23 people with pancreatic cancer. The goal was to find and count circulating tumor cells (cancer cells in the bl…
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
Can a simple RNA test predict pancreatic cancer outcomes?
Knowledge-focused CompletedThis study examined small RNA molecules called microRNAs in tissue samples from 57 people with pancreatic cancer. The samples were collected during a routine endoscopic ultrasound procedure. Researchers aimed to see if certain microRNA patterns are linked to how aggressive the ca…
Sponsor: Carol Davila University of Medicine and Pharmacy • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
New biomarker may predict which cancer drugs work best
Knowledge-focused CompletedThis completed study tested whether a new biomarker called 'mass response' can predict how well a cancer therapy will work. Researchers collected tumor cells from 72 patients with various cancers through fluid drainage or biopsies. The goal was to see if this biomarker could guid…
Sponsor: Travera Inc • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
Blood test could guide pancreatic cancer therapy
Knowledge-focused CompletedThis completed study looked at whether a simple blood test (liquid biopsy) can find genetic markers that predict how well pancreatic cancer treatments work. Researchers analyzed DNA from tumors circulating in the blood of 420 patients with pancreatic cancer. The goal was to disco…
Sponsor: National Cancer Center, Korea • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Heart risk alert: troponin test may protect cancer patients on immunotherapy
Knowledge-focused CompletedThis completed study looked at 300 cancer patients treated with immune checkpoint inhibitors to see if measuring troponin levels could help detect serious heart problems early. The goal was to prevent major cardiovascular events like heart attack or stroke without unnecessarily s…
Sponsor: Institut Mutualiste Montsouris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Cancer drug heart risk mystery probed in new study
Knowledge-focused CompletedThis study looked at how immune checkpoint inhibitors, a type of cancer drug, might affect blood vessels and increase heart risks. Researchers measured blood vessel function and checked for related markers in 39 cancer patients before and after starting treatment. The goal was to…
Sponsor: Institut Mutualiste Montsouris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
New 3D method may improve tumor measurement accuracy
Knowledge-focused CompletedThis study looked at 120 adults with breast, pancreatic, or biliary cancer to see if a new 3D measurement method (TDTP-RECIST) is better than the standard way (RECIST 1.1) for tracking tumor shrinkage before surgery. Researchers compared imaging results with actual tumor tissue r…
Sponsor: Shanghai Zhongshan Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC
-
Vinegar trick may help detect pancreatic cancer earlier
Knowledge-focused CompletedThis study tested whether squirting vinegar into the small intestine during an endoscopy can help collect pancreatic juice for cancer testing. 75 people with suspected pancreatic cancer took part. The goal was to see if this method works and find the best amount of vinegar and co…
Sponsor: Peking Union Medical College Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:03 UTC
-
Pharmacist Check-Ups catch dangerous drug Mix-Ups in cancer care
Knowledge-focused CompletedThis study tested whether having a clinical pharmacist review medications for cancer patients before they start treatment could prevent drug-related problems. Researchers observed 440 adults with solid tumors who were about to receive chemotherapy, immunotherapy, or oral targeted…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
New biopsy technique could improve pancreatic cancer diagnosis
Knowledge-focused CompletedThis study tested a newer biopsy method called fine-needle biopsy (FNB) for diagnosing pancreatic masses. Researchers wanted to see if FNB could provide better tissue samples than the standard fine-needle aspiration (FNA) without needing a cytologist on site. Fifty-two adults wit…
Sponsor: Baylor College of Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
PET scans may improve chemo decisions for abdominal cancer patients
Knowledge-focused CompletedThis pilot study looked at whether repeated FDG-PET/CT scans can help select patients and evaluate how well a special chemotherapy (PIPAC) works for cancer that has spread to the lining of the abdomen. 34 patients with various abdominal cancers were included. The goal was to see …
Sponsor: Odense University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Cancer drug side effect under the microscope: muscle enzyme spike studied
Knowledge-focused CompletedThis study looked at how often a muscle enzyme called CPK increases in people with solid tumors who are taking a type of targeted therapy called tyrosine kinase inhibitors (TKIs). Researchers measured CPK levels in routine blood tests from 154 patients and checked if high levels …
Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Simple test may spot frailty in elderly cancer patients
Knowledge-focused CompletedThis study looked at how common frailty is in people aged 70 and older with solid tumors who visited a cancer center. Researchers used a short questionnaire called VES-13 to screen patients before their doctor visit. They also compared the test results with the doctor's own judgm…
Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Trial or standard care? study reveals emotional toll on cancer patients
Knowledge-focused CompletedThis study compared anxiety, depression, and quality of life between 125 cancer patients who joined clinical trials and those who received standard treatment. Researchers used questionnaires to measure stress and emotional well-being. The goal was to understand how trial particip…
Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Can adding radiation to immunotherapy help advanced cancer patients? new study explores safety and 'Abscopal' effects
Knowledge-focused CompletedThis study looked at 42 adults with advanced solid tumors who were already on or about to start checkpoint inhibitor immunotherapy and also needed palliative radiotherapy for symptom relief. Researchers wanted to see if the combination was safe (less than 30% severe side effects)…
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC
-
Chatbot coaches cancer survivors on genetic testing
Knowledge-focused CompletedThis study tested a digital chatbot (called CATALYST) to help cancer survivors learn about genetic testing for inherited cancer risk. Fifty adults who had certain cancers (like breast, ovarian, or prostate) used the chatbot or received usual care. The goal was to see if the chatb…
Sponsor: Rutgers, The State University of New Jersey • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
New study aims to spot which pancreatic cysts could turn cancerous
Knowledge-focused CompletedThis study looked at 3,000 adults with pancreatic cysts to find better ways to tell harmless cysts from those that might become cancer. Researchers used imaging scans, cyst fluid analysis, and genetic markers to improve accuracy. The goal is to help doctors make better decisions …
Sponsor: Johns Hopkins University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
One surgery for pancreatic cancer and liver spread: safe or risky?
Knowledge-focused CompletedThis study looked at hospital records from Germany over 14 years to see how often surgeons remove both the pancreatic tumor and any liver metastases in a single operation. The goal was to understand current practice and check whether adding liver surgery increases the risk of dea…
Sponsor: Richard Hunger • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC
-
New study tackles bone pain caused by chemo-boosting drug
Knowledge-focused CompletedThis study watched 225 people with solid tumors who got a drug called G-CSF during chemotherapy. G-CSF can cause bone pain. Researchers measured pain levels and tracked what treatments (like pain relievers or other methods) helped. They also checked quality of life, fatigue, mood…
Sponsor: Ankara Etlik City Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:07 UTC
-
Simple frailty quiz may help predict chemo risks for seniors with stomach or bowel cancer
Knowledge-focused CompletedThis study looked at whether two simple frailty questionnaires (G8 and VES-13) can predict serious side effects from chemotherapy in people 65 and older with gastrointestinal cancers. Researchers followed 72 patients receiving standard chemotherapy and checked their frailty, nutr…
Sponsor: Ankara Etlik City Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:07 UTC
-
Researchers watch how SBRT works for liver and pancreatic tumors
Knowledge-focused CompletedThis study looked at how safe and effective a precise type of radiation therapy (SBRT) is for treating liver tumors, liver metastases, and pancreatic tumors. It involved 65 adult patients who were already scheduled for SBRT. The goal was to monitor and improve the treatment proce…
Sponsor: Institute of Oncology Ljubljana • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:06 UTC
-
Pancreatic cancer surgery showdown: which technique saves more lives?
Knowledge-focused CompletedThis study looked back at over 2,400 pancreatic cancer patients who had surgery with vein reconstruction. It compared those who had open surgery to those who had minimally invasive surgery (like laparoscopy or robot-assisted). The goal was to see which approach leads to fewer com…
Sponsor: First Affiliated Hospital Xi'an Jiaotong University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC
-
Tumor DNA in blood during surgery may predict pancreatic cancer outcomes
Knowledge-focused CompletedThis study looked at 40 patients with pancreatic cancer to measure circulating tumor DNA (ctDNA) in blood from a vein near the pancreas and in the arm, as well as in fluid from the belly, during surgery. The goal was to see if these DNA levels could help predict how the disease p…
Sponsor: University Hospital, Rouen • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
What drives cancer patients to get a second opinion?
Knowledge-focused CompletedThis study looked at 236 adults with breast, colorectal, or pancreatic cancer who sought a second opinion at the University of Colorado. Researchers reviewed medical records to see if patients stayed for treatment or went elsewhere. The goal was to understand what factors influen…
Sponsor: University of Colorado, Denver • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
New cancer drug interaction study: will antibiotics or antifungals change its effects?
Knowledge-focused CompletedThis study looks at how two common drugs—rifampicin (an antibiotic) and itraconazole (an antifungal)—affect the levels of a new cancer drug called BI 907828 in the blood. It involves 33 adults with advanced solid tumors who have not responded to previous treatments. Participants …
Phase 1 • Sponsor: Boehringer Ingelheim • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
Pesticide link to pancreatic cancer investigated in small study
Knowledge-focused CompletedThis study looked at whether organochlorine pesticides, which build up in body fat over time, are more common in people with pancreatic cancer. Researchers compared fat and urine samples from 56 patients undergoing surgery—some with pancreatic cancer and some without. The goal wa…
Sponsor: CHU de Reims • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:12 UTC
-
Cancer patients happier getting immunotherapy at home?
Knowledge-focused CompletedThis French study asked 49 cancer patients how they felt about switching from hospital to home-based immunotherapy. The goal was to see if home treatment improved their satisfaction with care. It was an observational study, meaning no new treatments were tested—just patient exper…
Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
Scientists try out new tools to feel how hard tumors are
Knowledge-focused CompletedThis study tested two new methods to measure pressure and stiffness inside solid tumors in 27 patients. One method uses a thin catheter to measure pressure directly, and the other uses sound waves like an ultrasound to check stiffness. The goal was to see if these measurements co…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:10 UTC
-
Blood cell changes may predict pancreatic cancer survival
Knowledge-focused CompletedThis study looked at 300 people with pancreatic cancer to see if changes in a specific type of tumor cell in the blood (called mesenchymal circulating tumor cells) could predict how well they respond to treatment and how long they live. Researchers tracked these cells over time i…
Sponsor: Guo ShiWei • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:10 UTC
-
Simple frailty quiz may predict chemo risks in seniors
Knowledge-focused CompletedThis study looked at whether two easy-to-use frailty checklists (FRAIL and FiND) can predict severe side effects from chemotherapy in adults aged 65 and older with gastrointestinal cancers. Researchers followed 84 patients who had already had surgery and were receiving standard c…
Sponsor: Ankara Etlik City Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC
-
Chemo nausea still a problem despite standard care, study finds
Knowledge-focused CompletedThis study tracked 300 cancer patients receiving their first round of chemotherapy to see how often nausea and vomiting still happen, even with standard anti-nausea medicines. Participants filled out questionnaires about their symptoms in the first 24 hours and up to 4 days after…
Sponsor: Centre Francois Baclesse • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:04 UTC
-
Question list boosts cancer Patients' confidence and reduces anxiety
Knowledge-focused CompletedThis study tested whether giving cancer patients a list of questions to ask their doctors helps them feel more empowered and less anxious. About 96 patients, along with nurses and doctors, took surveys and shared their experiences. The goal is to improve communication and make pa…
Sponsor: Marmara University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
New study aims to improve timing of palliative care for advanced illnesses
Knowledge-focused CompletedThis completed study observed 178 patients with advanced cancer, chronic kidney failure, or chronic lung diseases to assess their palliative care needs and survival factors. Researchers used two scoring tools to evaluate when and how to best introduce palliative care alongside re…
Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
Immunotherapy side effects under the microscope: new study monitors autoantibodies
Knowledge-focused CompletedThis completed study followed 183 cancer patients starting checkpoint inhibitor therapy to see how often they develop autoantibodies—proteins that can mistakenly attack the body's own tissues. Researchers collected blood samples to track changes in several types of autoantibodies…
Sponsor: CHU de Reims • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
App vs. paper: which diary boosts cancer pill adherence?
Knowledge-focused CompletedThis study tested whether an electronic diary app helps cancer patients take their oral medications more consistently than a traditional paper diary. A total of 124 adults with solid tumors or blood cancers were randomly assigned to use either the app or a paper diary to track th…
Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
Does surgery spread pancreatic cancer? new study investigates
Knowledge-focused CompletedThis study looked at 35 people having surgery for pancreatic cancer to see if moving the tumor during the operation causes more cancer DNA to enter the bloodstream. Researchers took blood samples before, during, and after surgery to track these DNA levels. The goal was to better …
Sponsor: University Hospital, Toulouse • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:00 UTC
-
Cancer patients with COVID: do early antiviral drugs help?
Knowledge-focused CompletedThis completed study looked at how well early COVID-19 antiviral therapies work in cancer patients. Researchers tracked 112 patients with solid tumors who received these treatments to see how many needed hospitalization within 14 days. The goal is to fill knowledge gaps and impro…
Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:58 UTC
-
Pancreatic cancer gene map could lead to smarter treatments
Knowledge-focused CompletedThis study looked at the genes in tumors from 332 people with advanced pancreatic cancer. The goal was to see if genetic changes could help doctors choose better treatments. Researchers compared genetic information with how patients responded to their first chemotherapy. This is …
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:58 UTC
-
Gene-Based dosing study aims to make cancer drug safer
Knowledge-focused CompletedThis early-phase study tested the safety and drug levels of belinostat in 17 patients with advanced solid tumors or blood cancers that had not responded to prior treatments. Researchers grouped patients by their UGT1A1 gene type to see if genetic differences affect how the drug i…
Phase 1 • Sponsor: Acrotech Biopharma Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:55 UTC
-
Robotic pancreatic surgery: how fast do patients recover?
Knowledge-focused CompletedThis study looked at how patients recover after robotic surgery to remove part of the pancreas (pancreaticoduodenectomy). It included 91 adults with tumors in the pancreas or nearby areas. The main goal was to see how long they stayed in the hospital and how quickly they returned…
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC
-
Lab-Grown mini tumors could someday guide pancreatic cancer treatment
Knowledge-focused CompletedThis study looked at whether it is safe and possible to grow mini-tumors (organoids) from pancreatic cancer samples in the lab. 60 patients with pancreatic cancer provided tumor tissue during surgery or biopsy. The goal was to see if these organoids could be used to test differen…
Sponsor: Prof. Dr. med. Dres. h.c. Jan Schmidt, MME • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC
-
Can removing drains sooner after pancreatic surgery cut infections?
Knowledge-focused CompletedThis study tested whether removing surgical drains early (4 days after surgery) instead of the usual 10-15 days reduces infections after pancreaticoduodenectomy, a major operation for pancreatic tumors. 141 patients were included, and those without a pancreatic leak were randomly…
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 26, 2026 18:52 UTC
-
Real-World chemotherapy patterns in advanced pancreatic cancer revealed
Knowledge-focused CompletedThis study observed 799 adults with advanced or metastatic pancreatic cancer in Korea to see which chemotherapy treatments doctors actually use and why. Researchers tracked treatment choices, survival times, and quality of life. The goal was to understand real-world practice, not…
Sponsor: Boryung Pharmaceutical Co., Ltd • Aim: Knowledge-focused
Last updated Jun 26, 2026 16:16 UTC
-
Gut bugs linked to pancreatic cancer spread in new study
Knowledge-focused CompletedThis study looked at whether the types of bacteria in the gut are linked to whether pancreatic cancer has spread to nearby lymph nodes. Researchers compared stool samples from 55 patients with and without lymph node spread. They hope to find bacterial and chemical clues that coul…
Sponsor: Peking Union Medical College Hospital • Aim: Knowledge-focused
Last updated Jun 26, 2026 14:25 UTC